Alpha-Amylase Mutants

Abstract

The invention relates to a variant of a parent Termamyl-like .alpha.-amylase, which exhibits an alteration in at least one of the following properties relative to said parent .alpha.-amylase: i) improved pH stability at a pH from 8 to 10.5; and/or ii) improved Ca.sup.2+ stability at pH 8 to 10.5, and/or iii) increased specific activity at temperatures from 10 to 60.degree. C.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of U.S. application Ser. No. 10/980,923, filed Nov. 4, 2004 which is a continuation of U.S. application no, 10/665,667, filed Sep. 19, 2003, which is a divisional of U.S. application Ser. No. 09/769,864, filed on Jan. 25, 2001, which is a divisional of U.S. application Ser. No. 09/183,412, filed on Oct. 30, 1998, and claims priority under 35 U.S.C. 119 of Danish application no. 1240/97, filed on Oct. 30, 1997, Danish application no. PA 1998 00936, filed on Jul. 14, 1998, U.S. provisional application No. 60/064,662, filed on Nov. 6, 1997 and U.S. provisional application No. 60/093,234, filed on Jul. 17, 1998, the contents of which are fully incorporated herein by reference.

FIELD OP THE INVENTION

[0002] The present invention relates to variants (mutants) of parent Termamyl-like .alpha.-amylases with higher activity at medium temperatures and/or high pH.

BACKGROUND OP THE INVENTION

[0003] .alpha.-Amylases (.alpha.-1,4-glucan-4-glucanohydrolases, EC 3.2.1.1) constitute a group of enzymes which catalyze hydrolysis of starch and other linear and branched 1,4-glucosidic oligo- and polysaccharides.

[0004] There is a very extensive body of patent and scientific literature relating to this industrially very important class of enzymes. A number of .alpha.-amylases such as Termamyl-like .alpha.-amylases variants are known from e.g. WO 90/11352, WO 95/10603, WO 95/26397, WO 96/23873 and WO 96/23874.

[0005] Among more recent disclosures relating to .alpha.-amylases, WO 96/23874 provides three-dimensional, X-ray crystal structural data for a Termamyl-like .alpha.-amylase which consists of the 300 N-terminal amino acid residues of the B. amyloliquefaciens .alpha.-amylase (BAN.TM.) and amino acids 301-483 of the C-terminal end of the B. licheniformis .alpha.-amylase comprising the amino acid sequence (the latter being available commercially under the tradename Termamyl.TM.), and which is thus closely related to the industrially important Bacillus .alpha.-amylases (which in the present context are embraced within the meaning of the term "Termamyl-like .alpha.-amylases", and which include, inter alia, the B. licheniformis, B. amyloliquefaciens (BAN.TM.) and B. stearothermophilus (BSG.TM.) .alpha.-amylases). WO 96/23874 further describes methodology for designing, on the basis of an analysis of the structure of a parent Termamyl-like .alpha.-amylase, variants of the parent Termamyl-like .alpha.-amylase which exhibit altered properties relative to the parent.

BRIEF DISCLOSURE OF THE INVENTION

[0006] The present invention relates to novel .alpha.-amylolytic variants (mutants) of a Termamyl-like .alpha.-amylase which exhibit improved wash performance (relative to the parent .alpha.-amaylase) at high pH and at a medium temperature.

[0007] The term "medium temperature" means in the context of the invention a temperature from 10.degree. C. to 60.degree. C., preferably 20.degree. C. to 50.degree. C., especially 30-40.degree. C.

[0008] The term "high pH" means the alkaline pH which today are used for washing, more specifically from about pH 8 to 10.5.

[0009] In the context of the invention a "low temperature .alpha.-amylase" means an .alpha.-amylase which has an relative optimum activity in the temperature range from 0-30.degree. C.

[0010] In the context of the invention a "medium temperature .alpha.-amylase" means an .alpha.-amylase which has an optimum activity in the temperature range from 30-60.degree. C. For instance, SP690 and SP722 .alpha.-amylases, respectively, are "medium temperature .alpha.-amylases.

[0011] In the context of the invention a "high temperature .alpha.-amylase" is an .alpha.-amylase having the optimum activity in the temperature range from 60-110.degree. C. For instance, Termamyl is a "high temperature .alpha.-amylase.

[0012] Alterations in properties which may be achieved in variants (mutants) of the invention are alterations in:

the stability of the Termamyl-like .alpha.-amylase at a pH from 8 to 10.5, and/or the Ca.sup.2+ stability at pH 8 to 10.5, and/or the specific activity at temperatures from 10 to 60.degree. C., preferably 20-50.degree. C., especially 30-40.degree. C.

[0013] It should be noted that the relative temperature optimum often is dependent on the specific pH used. In other words the relative temperature optimum determined at, e.g., pH 8 may be substantially different from the relative temperature optimum determined at, e.g., pH 10.

The Temperature's Influence on the Enzymatic Activity

[0014] The dynamics in the active site and surroundings are dependent on the temperature and the amino acid composition and of strong importance for the relative temperature optimum of an enzyme. By comparing the dynamics of medium and high temperature .alpha.-amylases, regions of importance for the function of high temperature .alpha.-amylases at medium temperatures can be determined. The temperature activity profile of the SP722 .alpha.-amaylase (SEQ ID NO: 2) and the B. licheniformis .alpha.-amylase (available from Novo Nordisk as Termamyl.RTM.) (SEQ ID NO: 4) are shown in FIG. 2.

[0015] The relative temperature optimum of SP722 in absolute activities are shown to be higher at medium range temperatures (30-60.degree. C.) than the homologous B. licheniformis .alpha.-amylase, which have an optimum activity around. 60-100.degree. C. The profiles are mainly dependent on the temperature stability and the dynamics of the active site residues and their surroundings. Further, the activity profiles are dependent on the pH used and the pKa of the active site residues.

[0016] In the first aspect the invention relates to a variant of a parent Termamyl-like .alpha.-amylase, which variant has .alpha.-amylase activity, said variant comprises one or more mutations corresponding to the following mutations in the amino acid sequence shown in SEQ ID NO: 2:

T141, K142, F143, D144, F145, P146, G147, R148, G149,

Q174, R181, G182, D183, G184, K185, A186, W189, S193, N195,

H107, K108, G109, D166, W167, D168, Q169, S170, R171, Q172, F173,

F267, W268, K269, N270, D271, L272, G273, A274, L275, K311, E346,

F385, G456, N457, K458, P459, G460, T461, V462, T463.

[0017] A variant of the invention have one or more of the following substitutions or deletions:

TABLE-US-00001 T141A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, W, Y, V K142A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; F143A, D, R, N, C, E, Q, G, H, I, L, K, M, P, S, T, W, Y, V; D144A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; F145A, D, R, N, C, E, Q, G, H, I, L, K, M, P, S, T, W, Y, V; P146A, D, R, N, C, E, Q, G, H, I, L, K, M, F, S, T, W, Y, V; G147A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; R148A, D, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; G149A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; R181*, A, D, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; G182*, A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; D183*, A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; G184*, A, R, D, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; K185A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; A186D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; W189A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, Y, V; S193A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, T, W, Y, V; N195A, D, R, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; H107A, D, R, N, C, E, Q, G, I, L, K, M, F, P, S, T, W, Y, V; K108A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; G109A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; D166A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; W167A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, Y, V; D168A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; Q169A, D, R, N, C, E, G, H, I, L, K, M, F, P, S, T, W, Y, V; S170A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, T, W, Y, V; R171A, D, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; Q172A, D, R, N, C, E, G, H, I, L, K, M, F, P, S, T, W, Y, V; F173A, D, R, N, C, E, Q, G, H, I, L, K, M, P, S, T, W, Y, V; Q174*, A, D, R, N, C, E, G, H, I, L, K, M, F, P, S, T, W, Y, V; F267A, D, R, N, C, E, Q, G, H, I, L, K, M, P, S, T, W, Y, V; W268A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, Y, V; K269A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; N270A, D, R, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; D271A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; L272A, D, R, N, C, E, Q, G, H, I, K, M, F, P, S, T, W, Y, V; G273A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; A274D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; L275A, D, R, N, C, E, Q, G, H, I, K, M, F, P, S, T, W, Y, V; K311A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; E346A, D, R, N, C, Q, G, H, I, K, L, M, F, P, S, T, W, Y, V; K385A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; G456A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; N457A, D, R, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; K458A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; P459A, D, R, N, C, E, Q, G, H, I, L, K, M, F, S, T, W, Y, V; G460A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; T461A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, W, Y, V; V462A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y; T463A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, W, Y, V.

[0018] Preferred are variants having one or more of the following substitutions or deletions:

K142R; S193P; R195F; K269R,Q; N270Y,R,D; K311R; E346Q; K385R; K458R; P459T; T461P; Q174*; R181Q,N,S; G182T,S,N; D183*; G184*; K185A,R,D,C,E,Q,G,H,I,L,M,N,F,P,S,T,W,Y,V; A186T,S,N,I,V,R; W189T,S,N,Q.

[0019] Especially preferred are variants having a deletion in positions D183 and G184 and further one or more of the following substitutions or deletions;

K142R; S193P; N195F; K269R,Q; N270Y,R,D; K311R; E346Q; K385R; K458R; P459T; T461P; Q174*; R181Q,N,S; G182T,S,N;

K185A,R,D,C,E,Q,G,H,I,L,M,N,F,P,S,T,W,Y,V; A186T,S,N,I,V,R; W189T,S,N,Q.

[0020] The variants of the invention mentioned above exhibits an alteration in at least one of the following properties relative to the parent .alpha.-amylase:

i) improved pH stability at a pH from 8 to 10.5; and/or ii) improved Ca.sup.2+ stability at pH 8 to 10.5, and/or iii) increased specific activity at temperatures from 10 to 60.degree. C., preferably 20-50.degree. C., especially 30-40.degree. C. Further, details will be described below.

[0021] The invention further relates to DNA constructs encoding variants of the invention; to methods for preparing variants of the invention; and to the use of variants of the invention, alone or in combination with other enzymes, in various industrial products or processes, e.g., in detergents or for starch liquefaction.

[0022] In a final aspect the invention relates to a method of providing .alpha.-amylases with altered pH optimum, and/or altered temperature optimum, and/or improved stability,

Nomenclature

[0023] In the present, description and claims, the conventional one-letter and three-letter codes for amino acid residues are used. For ease of reference, .alpha.-amylase variants of the invention are described by use of the following nomenclature:

Original amino acid(s):position(s):substituted amino acid is)

[0024] According to this nomenclature, for instance the substitution of alanine for asparagine in position 30 is shown as:

[0025] Ala30Asn or A30N

a deletion of alanine in the same position is shown as:

[0026] Ala30*or A30*

and insertion of an additional amino acid residue, such as lysine, is shown as:

[0027] Ala30AlaLys or A3 OAK

[0028] A deletion of a consecutive stretch of amino acid residues, such as amino acid residues 30-33, is indicated as (30-33)* or .DELTA.(A30-N33).

[0029] Where a specific .alpha.-amylase contains a "deletion" in comparison with other .alpha.-amylases and an insertion is made in such a position this is indicated as:

[0030] *36Asp or *36D

for insertion of an aspartic acid in position 36 Multiple mutations are separated by plus signs, i.e.:

[0031] Ala30Asp+ Glu34Ser or A30N+E34S

representing mutations in positions 30 and 34 substituting alanine and glutamic acid for asparagine and serine, respectively.

[0032] When one or more alternative amino acid residues may be inserted in a given position it is indicated as

[0033] A30N,E or

[0034] A30N or A30E

[0035] Furthermore, when a position suitable for modification is identified herein without any specific modification being suggested, it is to be understood that any amino acid residue may be substituted for the amino acid residue present in the position.

[0036] Thus, for instance, when a modification of an alanine in position 30 is mentioned, but not specified, it is to be understood that the alanine may be deleted or substituted for any other amino acid, i.e., any one of:

R,N,D,A,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V.

BRIEF DESCRIPTION OF THE DRAWING

[0037] FIG. 1 is an alignment of the amino acid sequences of six parent Termamyl-like .alpha.-amylases. The numbers on the extreme left designate the respective amino acid sequences as follows;

1: SEQ ID NO: 2

2: Kaoamyl

3: SEQ ID NO: 1

4: SEQ ID NO; 5

5: SEQ ID NO: 4

6: SEQ ID NO: 3.

[0038] FIG. 2 shows the temperature activity profile of SP722 (SEQ ID NO: 2) (at pH 9) and B. licheniformis .alpha.-amylase (SEQ ID NO: 4) (at pH 7.3).

[0039] FIG. 3 shows the temperature profile for SP690 (SEQ ID NO: 1), SP722 (SEQ ID NO: 2), B. licheniformis .alpha.-amylase (SEQ ID NO: 4) at pH 10.

[0040] FIG. 4 is an alignment of the amino acid sequences of five .alpha.-amylases. The numbers on the extreme left designate the respective amino acid sequences as follows:

1; amyp_mouse 2: amyp_rat 3: amyp_pig porcine pancreatic alpha-amylase (PPA) 4: amyp_human 5: amy_altha A. haloplanctis alpha-amylase (AHA)

DETAILED DISCLOSURE OF THE INVENTION

The Termamyl-Like .alpha.-Amylase

[0041] It is well known that a number of .alpha.-amylases produced by Bacillus spp. are highly homologous on the amino acid level. For instance, the B. licheniformis .alpha.-amylase comprising the amino acid sequence shown in SEQ ID NO: 4 (commercially available as Termamyl.TM.) has been found to be about 89% homologous with the B. amyloliquefaciens .alpha.-amylase comprising the amino acid sequence shown in SEQ ID NO: 5 and about 79% homologous with the B. stearothermophilus .alpha.-amylase comprising the amino acid sequence shown in SEQ ID NO: 3. Further homologous .alpha.-amylases include an .alpha.-amylase derived from a strain of the Bacillus Bp. NCIB 12289, NCIB 12512, NCIB 12513 or DSM 9375, all of which are described in detail in WO 95/26397, and the .alpha.-amylase described by Tsukamoto et al., Biochemical and Biophysical Research Communications, 151 (1988), pp. 25-31, (see SEQ ID NO: 6).

[0042] Still further homologous .alpha.-amylases include the .alpha.-amylase produced by the B. licheniformis strain described in BP 0252666 (ATCC 27811), and the .alpha.-amylases identified in WO 91/00353 and WO 94/18314. Other commercial Termamyl-like B. licheniformis .alpha.-amylases are comprised in the products Optitherm.TM. and Takatherm.TM. (available from Solvay), Maxamyl.TM. (available from Gist-brocades/Genencor), Spezyro AA.TM. and Spezyme Delta AA.TM. (available from Genencor), and Keistase.TM. (available from Daiwa).

[0043] Because of the substantial homology found between these .alpha.-amylases, they are considered to belong to the same class of .alpha.-amylases, namely the class of "Termamyl-like .alpha.-amylases".

[0044] Accordingly, in the present context, the term "Termamyl-like a amylase" is intended to indicate an .alpha.-amylase which, at the amino acid level, exhibits a substantial homology to Termamyl.TM., i.e., the B. licheniformis .alpha.-amylase having the amino acid sequence shown in SEQ ID NO:4 herein. In other words, all the following .alpha.-amylases which has the amino acid sequences shown in SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7 or 8 herein, or the amino acid sequence shown in SEQ ID NO: 1 of WO 95/26397 (the same as the amino acid sequence shown as SEQ ID NO: 7 herein) or in SEQ ID NO: 2 of WO 95/26397 (the same as the amino acid sequence shown as SEQ ID NO: 8 herein) or in Tsukamoto et al., 1988, (which amino acid sequence is shown in SEQ ID NO: 6 herein) are considered to be "Termamyl-like .alpha.-amylase". Other Termamyl-like .alpha.-amylases are .alpha.-amylases i) which displays at least 60%, such as at least 70%, e.g., at least 75%, or at least 80%, e.g., at least 85%, at least 90% or at least 95% homology with at least one of said amino acid sequences shown in SEQ ID NOS: 1-8 and/or ii) displays immunological cross-reactivity with an antibody raised against at least one of said .alpha.-amylases, and/or iii) is encoded by a DMA sequence which hybridizes to the DNA sequences encoding the above-specified a amylases which are apparent from SEQ ID NOS: 9, 10, 11, or 12 of the present application (which encoding sequences encode the amino acid sequences shown in SEQ ID NOS: 1, 2, 3, 4 and 5 herein, respectively), from SEQ ID NO: 4 of WO 95/26397 (which DNA sequence, together with the stop codon TAA, is shown in SEQ ID NO: 13 herein and encodes the amino acid sequence shown in SEQ ID NO; 8 herein) and from SEQ ID NO: 5 of WO 95/26397 (shown in SEQ ID NO: 14 herein), respectively.

[0045] In connection with property i), the "homology" may be determined by use of any conventional algorithm, preferably by use of the GAP progamme from the GCG package version 7.3 (June 1993) using default values for GAP penalties, which is a GAP creation penalty of 3.0 and GAP extension penalty of 0.1, (Genetic Computer Group (1991) Programme Manual for the GCG Package, version 7, 575 Science Drive, Madison, Wis., USA 53711).

[0046] A structural alignment between Termamyl (SEQ ID NO: 4) and a Termamyl-like .alpha.-amylase may be used to identify equivalent/corresponding positions in other Termamyl-like .alpha.-amylases. One method of obtaining said structural alignment is to use the Pile Up programme from the GCG package using default values of gap penalties, i.e., a gap creation penalty of 3.0 and gap extension penalty of 0.1. Other structural alignment methods include the hydrophobic cluster analysis (Gaboriaud et al., (1987), FSBS LETTERS 224, pp. 149-155) and reverse threading (Huber, T; Torda, A E, PROTEIN SCIENCE Vol. 7, No. 1 pp. 142-149 (1998).

[0047] Property ii) of the .alpha.-amylase, i.e., the immunological cross reactivity, may be assayed using an antibody raised against, or reactive with, at least one epitope of the relevant Termamyl-like .alpha.-amylase. The antibody, which may either be monoclonal or polyclonal, may be produced by methods known in the art, e.g., as described by Hudson et al., Practical Immunology, Third edition (1989), Blackwell Scientific Publications. The immunological cross-reactivity may be determined using assays known in the art, examples of which are Western Blotting or radial immunodiffusion assay, e.g., as described by Hudson et al., 1989. In this respect, immunological cross-reactivity between the .alpha.-amylases having the amino acid sequences SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, or 8, respectively, has been found.

[0048] The oligonucleotide probe used in the characterisation of the Termamyl-like .alpha.-amylase in accordance with property iii) above may suitably be prepared on the basis of the full or partial nucleotide or amino acid sequence of the .alpha.-amylase in question.

[0049] Suitable conditions for testing hybridisation involve pre-soaking in 5.times.SSC and prehybridising for 1 hour at -40.degree. C. in a solution of 20% formamide, 5.times.Denhardt's solution, 50 mM sodium phosphate, pH 6.8, and 50 mg of denatured sonicated calf thymus DNA, followed by hybridisation in the same solution supplemented with 100 mM ATP for 18 hours at -40.degree. C., followed by three times washing of the filter in 2.times.SSC, 0.2% SDS at 40.degree. C. for 30 minutes (low stringency), preferred at 50.degree. C. (medium stringency), more preferably at 65.degree. C. (high stringency), even more preferably at .about.75.degree. C. (very high stringency). More details about the hybridisation method can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989.

[0050] In the present context, "derived from" is intended not only to indicate an .alpha.-amylase produced or producible by a strain of the organism in question, but also an .alpha.-amylase encoded by a DNA sequence isolated from such strain and produced in a host organism transformed with said DNA sequence. Finally, the term is intended to indicate an .alpha.-amylase which is encoded by a DNA sequence of synthetic and/or cDNA origin and which has the identifying characteristics of the .alpha.-amylase in question. The term is also intended to indicate that the parent .alpha.-amylase may be a variant of a naturally occurring .alpha.-amylase, i.e. a variant which is the result of a modification (insertion, substitution, deletion) of one or more amino acid residues of the naturally occurring .alpha.-amylase.

Parent Hybrid .alpha.-Amylases

[0051] The parent .alpha.-amylase (i.e., backbone .alpha.-amylase) may be a hybrid .alpha.-amylase, i.e., an .alpha.-amylase which comprises a combination of partial amino acid sequences derived from at least two .alpha.-amylases.

[0052] The parent hybrid .alpha.-amylase may be one which on the basis of amino acid homology and/or immunological cross-reactivity and/or DNA hybridisation (as defined above) can be determined to belong to the Termamyl-like .alpha.-amylase family. In this case, the hybrid .alpha.-amylase is typically composed of at least one part of a Termamyl-like .alpha.-amylase and part(s) of one or more other .alpha.-amylases selected from Termamyl-like .alpha.-amylases or non-Termamyl-like .alpha.-amylases of microbial (bacterial or fungal) and/or mammalian origin.

[0053] Thus, the parent hybrid .alpha.-amylase may comprise a combination of partial amino acid sequences deriving from at least two Termamyl-like .alpha.-amylases, or from at least one Termamyl-like and at least one non-Termamyl-like bacterial .alpha.-amylase, or from at least one Termamyl-like and at least one fungal .alpha.-amylase. The Termamyl-like .alpha.-amylase from which a partial amino acid sequence derives may, e.g., be any of those specific Termamyl-like .alpha.-amylase referred to herein.

[0054] For instance, the parent .alpha.-amylase may comprise a C-terminal part: of an .alpha.-amylase derived from a strain of B. licheniformis, and a N-terminal part of an .alpha.-amylase derived from a strain of B. amyloliquefaciens or from a strain of B. stearothermophilus. For instance, the parent .alpha.-amylase may comprise at least 430 amino acid residues of the C-terminal part of the B. licheniformis .alpha.-amylase, and may, e.g., comprise a) an amino acid segment corresponding to the 37 N-terminal amino acid residues of the B. amyloliquefaciens .alpha.-amylase having the amino acid sequence shown in SEQ ID NO: 5 and an amino acid segment corresponding to the 445 C-terminal amino acid residues of the B. licheniformis .alpha.-amylase having the amino acid sequence shown in SEQ ID NO: 4, or a hybrid Termamyl-like .alpha.-amylase being identical to the Termamyl sequence, i.e., the Bacillus licheniformis .alpha.-amylase shown in SEQ ID NO: 4, except that the N-terminal 35 amino acid residues (of the mature protein) has been replaced by the N-terminal 33 residues of BAN (mature protein), i.e., the Bacillus amyloliquefaciens .alpha.-amylase shown in SEQ ID NO: 5; or b) an amino acid, segment corresponding to the 68 N-terminal amino acid residues of the B. stearothermophilus .alpha.-amylase having the amino acid sequence shown in SEQ ID NO: 3 and an amino acid segment corresponding to the 415 C-terminal amino acid residues of the B. licheniformis .alpha.-amylase having the amino acid sequence shown in SEQ ID NO: 4.

[0055] Another suitable parent hybrid .alpha.-amylase is the one previously described in WO 96/23374 (from Novo Nordisk) constituting the N-terminus of BAN, Bacillus amyloliquefaciens .alpha.-amylase (amino acids 1-300 of the mature protein) and the C-terminus from Termamyl (amino acids 301-483 of the mature protein). Increased activity was achieved by substituting one or more of the following positions of the above hybrid .alpha.-amylase (BAN:1-300/Termamyl:301-483); Q360, F290, and N.sub.102. Particularly interesting substitutions are one or more of the following substitutions: Q360E,D; F290A, C, D, E, G, H, I, K, L, M, N, P,Q, R,S,T; N.sub.102D, E;

[0056] The corresponding positions in the SP722 .alpha.-amylase shown in SEQ ID NO: 2 are one or more of: S365, Y2 95, N106. Corresponding substitutions of particular interest in said .alpha.-amylase shown in SEQ ID NO: 2 are one or more of: S365D,E; Y295A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T; and N106D,E.

[0057] The corresponding positions in the SP690 .alpha.-amylase shown in SEQ ID NO: 1 are one or more of: S365, Y295, N.sub.106. The corresponding substitutions of particular interest are one or more of: S365D,E; Y295 A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T; N106D.E.

[0058] The above mentioned non-Termamyl-like .alpha.-amylase may, e.g., be a fungal .alpha.-amylase, a mammalian or a plant .alpha.-amylase or a bacterial .alpha.-amylase (different from a Termamyl-like .alpha.-amylase). Specific examples of such .alpha.-amylases include the Aspergillus oryzae TAKA .alpha.-amylase, the A. niger acid .alpha.-amylase, the Bacillus subtilis .alpha.-amylase, the porcine pancreatic .alpha.-amylase and a barley .alpha.-amylase. All of these .alpha.-amylases have elucidated structures which are markedly different from the structure of a typical Termamyl-like .alpha.-amylase as referred to herein.

[0059] The fungal .alpha.-amylases mentioned above, i.e., derived from A. niger and A. oryzae, are highly homologous on the amino acid level and generally considered to belong to the same family of .alpha.-amylases. The fungal .alpha.-amylase derived from Aspergillus oryzae is commercially available under the tradename Fungamyl.TM..

[0060] Furthermore, when a particular variant of a Termamyl-like .alpha.-amylase (variant of the invention) is referred to--in a conventional manner--by reference to modification (e.g., deletion or substitution) of specific amino acid residues in the amino acid sequence of a specific Termamyl-like .alpha.-amylase, it is to be understood that variants of another Termamyl-like .alpha.-amylase modified in the equivalent position(s) (as determined from the best possible amino acid sequence alignment between the respective amino acid sequences) are encompassed thereby.

[0061] In a preferred embodiment of the invention the .alpha.-amylase backbone is derived from B. licheniformis (as the parent Termamyl-like .alpha.-amylase), e.g., one of those referred to above, such as the B. licheniformis .alpha.-amylase having the amino acid sequence shown in SEQ ID NO: 4.

Altered Properties of Variants of the Invention

[0062] The following discusses the relationship between mutations which are present in variants of the invention, and desirable alterations in properties (relative to those a parent Termamyl-like .alpha.-amylase) which may result therefrom.

Improved Stability at pH 8-10.5

[0063] In the context of the present invention, mutations (including amino acid substitutions) of importance with respect to achieving improved stability at high pH (i.e., pH 8-10.5) include mutations corresponding to mutations in one or more of the following positions in SP722 .alpha.-amylase (having the amino acid sequence shown in SEQ ID NO: 2): T141, K142, F143, D144, F145, P146, G147, R148, G149, R181, A186, S193, N195, K269, N270, K311, K458, P459, T461.

[0064] The variant of the invention have one or more of the following substitutions (using the SEQ ID NO: 2 numbering):

TABLE-US-00002 T141A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, W, Y, V; K142A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; F143A, D, R, N, C, E, Q, G, H, I, L, K, M, P, S, T, W, Y, V; D144A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; F145A, D, R, N, C, E, Q, G, H, I, L, K, M, P, S, T, W, Y, V; P146A, D, R, N, C, E, Q, G, H, I, L, K, M, F, S, T, W, Y, V; G147A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; R148A, D, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; G149A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; K181A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; A186D, R, N, C, E, Q, G, H, I, L, P, K, M, F, S, T, W, Y, V; S193A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, T, W, Y, V; N195A, D, R, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; K269A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; N270A, D, R, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; K311A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; K458A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; P459A, D, R, N, C, E, Q, G, H, I, L, K, M, F, S, T, W, Y, V; T461A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, W, Y, V.

[0065] Preferred, high pH stability variants include one or more of the following substitutions in the SP722 .alpha.-amylase (having the amino acid sequence shown in SEQ ID NO: 2):

K142R, R1813, A186T, S193P, N195F, K269R, N270Y, K311R, K458R, P459T and T461P.

[0066] In specific embodiments the Bacillus strain NCIB 12512 .alpha.-amylase having the sequence shown in SEQ ID NO: 1, or the B. stearothermophilus .alpha.-amylase having the sequence shown in SEQ ID NO: 3, or the B. licheniformis .alpha.-amylase having the sequence shown in SEQ ID NO: 4, or the S, amyloliquefaciens .alpha.-amylase having the sequence shown in SEQ ID NO: 5 is used as the backbone, i.e., parent Termamyl-like .alpha.-amylase, for these mutations.

[0067] As can been seen from the alignment in FIG. 1 the B. stearothermophilus .alpha.-amylase already has a Tyrosine at position corresponding to N270 in SP722. Further, the Bacillus strain NCIB 12512 .alpha.-amylase, the B. stearothermophilus .alpha.-amylase, the B. licheniformis .alpha.-amylase and the B. amyloliquefaciens .alpha.-amylase already have Arginine at position corresponding to K458 in SP722. Furthermore, the B. licheniformis .alpha.-amylase already has a Proline at position corresponding to T461 in SP722. Therefore, for said .alpha.-amylases these substitutions are not relevant.

[0068] .alpha.-amylase variants with improved stability at high pH can be constructed by making substitutions in the regions found using the molecular dynamics simulation mentioned in Example 2. The simulation depicts the region(s) that has a higher flexibility or mobility at high pH (i.e., pH 8-10.5) when compared to medium pH.

[0069] By using the structure of any bacterial alpha-amylase with homology (as defined below) to the Termamyl-like .alpha.-amylase (BA2), of which the 3D structure is disclosed in Appendix 1 of WO 96/23874 (from Novo Nordisk), it is possible to model build the structure of such alpha-amylase and to subject it to molecular dynamics simulations. The homology of said bacterial .alpha.-amylase may be at least 60%, preferably be more than 70%, more preferably more than 80%, most preferably more than 90% homologous to the above mentioned Termamyl-like .alpha.-amylase (BA2), measured using the UWGCG GAP program from the GCG package version 7.3 (June 1993) using default values for GAP penalties [Genetic Computer Group (1991) Programme Manual for the GCG Package, version 7, 575 Science Drive, Madison, Wis., USA 53711], Substitution of the unfavorable residue for another would be applicable.

Improved Ca.sup.2+ Stability at pH 8-10.5.

[0070] Improved Ca stability means the stability of the enzyme under Ca.sup.+ depletion has been improved. In the context of the present invention, mutations (including amino acid substitutions) of importance with respect to achieving improved Ca.sup.2+ stability at high pH include mutation or deletion in one or more positions corresponding to the following positions in the SP722 .alpha.-amylase having the amino acid sequence shown in SEQ ID NO; 2: R181, G182, D183, G184, K185, A18S, W189, M195, N270, E346, K385, K458, P459.

[0071] A variant of the invention have one or more of the following substitutions or deletions:

TABLE-US-00003 R181*, A, D, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; G182*, A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; D183*, A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; G184*, A, R, D, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; K185A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; A186D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; W189A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, Y, V; N195A, D, R, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; N270A, R, D, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; E346A, R, D, N, C, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; K385A, R, D, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; K458A, R, D, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; P459A, R, D, N, C, E, Q, G, H, I, L, K, M, F, S, T, W, Y, V.

[0072] Preferred are variants having one or more of the following substitutions or deletions:

R181Q,N; G182T,S,N; D183*; G184*;

K185A,R,D,C,E,Q,G,H,I,L,F,P,S,T,W,Y,V; A186T,S,N,I,V;

W189T,S,N,Q; N195F, N27GR,D; E346Q; K385R; K458R; P459T.

[0073] In specific embodiments the Bacillus strain NCIB 12512 .alpha.-amylase having the sequence shown in SEQ ID NO: 1, or the B. amyloliquefaciens .alpha.-amylase having the sequence shown in SEQ ID NO: 5, or the B. licheniformis .alpha.-amylase having the sequence shown in SEQ ID NO: 4 are used as the backbone for these mutations.

[0074] As can been seen from the alignment in FIG. 1 the B. licheniformis .alpha.-amylase does not have the positions corresponding to D183 and G184 in SP722. Therefore for said .alpha.-amylases these deletions are not relevant.

[0075] In a preferred embodiment the variant is the Bacillus strain NCTB 12512 .alpha.-amylase with deletions in D183 and G184 and further one of the following substitutions: R181Q,N and/or G182T,S,N and/or D183*; G184* and/or

K185A,R, D, C, E, Q, G, H,I,L,M,N,F,P,S,T,W,Y,V and/or A186T,S,N,I,V and/or W189T,S,N,Q and/or N195F and/or N270R,D and/or E346Q and/or F385R and/or K458R and/or P459T,

Increased Specific Activity at Medium Temperature

[0076] In a further aspect of the present invention, important mutations with respect to obtaining variants exhibiting increased specific activity at temperatures from 10-60.degree. C., preferably 20-50.degree. C., especially 30-40.degree. C., include mutations corresponding to one or more of the following positions in the SP722 .alpha.-amylase having the amino acid sequence shown in SEQ ID NO: 2:

H107, K108, G109, D166, W167, D168, Q169, S170, R171, Q172, F173, Q174, D183, G184, N195, F267, W268, K269, N270, D271, L272, G273, A274, L275, G456, N457, K458, P459, G460, T461, V462, T463.

[0077] The variant, of the invention have one or more of the following substitutions:

TABLE-US-00004 H107A, D, R, N, C, E, Q, G, I, L, K, M, F, P, S, T, W, Y, V; K108A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; G109A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; D166A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; W167A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, Y, V; D168A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; Q169A, D, R, N, C, E, G, H, I, L, K, M, F, P, S, T, W, Y, V; S170A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, T, W, Y, V; R171A, D, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; Q172A, D, R, N, C, E, G, H, I, L, K, M, F, P, S, T, W, Y, V; F173A, D, R, N, C, E, Q, G, H, I, L, K, M, P, S, T, W, Y, V; Q174*, A, D, R, N, C, E, G, H, I, L, K, M, F, P, S, T, W, Y, V; D183*, A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, W, Y, V; G184*, A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; N195A, D, R, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; F267A, D, R, N, C, E, Q, G, H, I, L, K, M, P, S, T, W, Y, V; W268A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, Y, V; K269A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; N270A, D, R, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; D271A, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; L272A, D, R, N, C, E, Q, G, H, I, K, M, F, P, S, T, W, Y, V; G273A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; A274D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; L275A, D, R, N, C, E, Q, G, H, I, K, M, F, P, S, T, W, Y, V; G456A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; N457A, D, R, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, V; K458A, D, R, N, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V; P459A, D, R, N, C, E, Q, G, H, I, L, K, M, F, S, T, W, Y, V; G460A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, V; T461A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, W, Y, V; V462A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y; T463A, D, R, N, C, E, Q, G, H, I, L, K, M, F, P, S, W, Y, V.

[0078] Preferred variants has one or more of the following substitutions or deletions: .quadrature.174*, D183*, G184*, K269S.

[0079] In a specific embodiment the B. licheniformis .alpha.-amylase having the sequence shown in SEQ ID NO: 4 is used as the backbone for these mutations.

General Mutations in Variants Invention: Increased Specific Activity at Medium Temperatures

[0080] The particularly interesting amino acid substitution are those that increase the mobility around the active site of the enzyme. This is accomplished by changes that disrupt stabilizing interaction in the vicinity of the active site, i.e., within preferably 10 .ANG. or 8 .ANG. or 6 .ANG. or 4 .ANG. from any of the residues constituting the active site.

[0081] Examples are mutations that reduce the size of side chains, such as

Ala to Gly,

Val to Ala or Gly,

Ile or Leu to Val, Ala, or Gly

Thr to Ser

[0082] Such mutations are expected to cause increased flexibility in the active site region either by the introduction of cavities or by the structural rearrangements that fill the space left by the mutation.

[0083] It may be preferred that a variant of the invention comprises one or more modifications in addition to those outlined above. Thus, it may be advantageous that one or more Proline residues present in the part of the .alpha.-amylase variant which is modified is/are replaced with a non-Proline residue which may be any of the possible, naturally occurring non-Proline residues, and which preferably is an Alanine, Glycine, Serine, Threonine, Valine or Leucine.

[0084] Analogously, it may be preferred that one or more Cysteine residues present among the amino acid residues with which the parent .alpha.-amylase is modified is/are replaced with a non-Cysteine residue such as Serine, Alanine, Threonine, Glycine, Valine or Leucine.

[0085] Furthermore, a variant of the invention may--either as the only modification or in combination with any of the above outlined modifications--be modified so that one or more Asp and/or Glu present in an amino acid fragment corresponding to the amino acid fragment 185-209 of SEQ ID NO: 4 is replaced by an Asn and/or Gln, respectively. Also of interest is the replacement, in the Termamyl-like .alpha.-amylase, of one or more of the Lys residues present in an amino acid fragment corresponding to the amino acid fragment 185-209 of SEQ ID NO: 4 by an Arg.

[0086] It will be understood that the present invention encompasses variants incorporating two or more of the above outlined modifications.

[0087] Furthermore, it may be advantageous to introduce point-mutations in any of the variants described herein.

.alpha.-Amylase Variants Having Increased Mobility Around the Active Site:

[0088] The mobility of .alpha.-amylase variants of the invention may be increased by replacing one or more amino acid residue at one or more positions close to the substrate site. These positions are (using the SP722 .alpha.-amylase (SEQ ID NO: 2) numbering): V56, K108, D168, Q169, Q172, L201, K269, L272, L275, K446, P45S.

[0089] Therefore, in an aspect the invention relates to variants being mutated in one or more of the above mentioned positions.

[0090] Preferred substitutions are one or more of the following:

TABLE-US-00005 V56A, G, S, T; K108A, D, E, Q, G, H, I, L, M, N, S, T, V; D168A, G, I, V, N, S, T; Q169A, D, G, H, I, L, M, N, S, T, V; Q172A, D, G, H, I, L, M, N, S, T, V; L201A, G, I, V, S, T; K269A, D, E, Q, G, H, I, L, M, N, S, T, V; L272A, G, I, V, S, T; L275A, G, I, V, S, T; Y295A, D, E, Q, G, H, I, L, M, N, F, S, T, V; K446A, D, E, Q, G, H, I, L, M, N, S, T, V; P459A, G, I, L, S, T, V.

[0091] In specific embodiments of the invention the Bacillus strain NCIB 12512 .alpha.-amylase having the sequence shown in SEQ ID NO: 1, or the B. stearothermophilus ex-amylase having the sequence shown in SEQ ID NO: 3, or the B. licheniformis .alpha.-amylase having the sequence shown in SEQ ID NO; 4, or the B. amyloliquefaciens .alpha.-amylase having the sequence shown in SEQ ID NO: 5 are used as the backbone for these mutations.

[0092] As can been seen from the alignment in FIG. 1 the B. licheniformis .alpha.-amylase and the B. amyloliquefaciens .alpha.-amylase have a Glut amine at position corresponding to K269 in SP722. Further, the B. stearothermophilus .alpha.-amylase has a Serine at position corresponding to K269 in SP722Therefore, for said .alpha.-amylases these substitutions are not relevant.

[0093] Furthermore, as can been seen from the alignment in FIG. 1 the B. amyloliquefaciens .alpha.-amylase has an Alanine at position corresponding to L272 in SP722, and the B. stearothermophilus .alpha.-amylase has a Isoleucine at the position corresponding to L272 in SP722. Therefore, for said .alpha.-amylases these substitutions are not relevant.

[0094] As can been seen from the alignment in FIG. 1, the Bacillus strain 12512 .alpha.-amylase has a Isoleucine at position corresponding to L275 in SP722. Therefore for said .alpha.-amylase this substitution is not relevant.

[0095] As can been seen from the alignment in FIG. 1 the B. amyloliquefaciens .alpha.-amylase has a Phenylalanine at position corresponding to 295 in SP722. Further, the B. stearothermophilus .alpha.-amylase has an Asparagine at position corresponding to Y295 in SP722. Therefore, for said .alpha.-amylases these substitutions are not relevant.

[0096] As can been seen from the alignment in FIG. 1 the B. licheniformis .alpha.-amylase and the B. amyloliquefaciens .alpha.-amylase have a Asparagine at position corresponding to K446 in SP722. Further, the B. stearothermophilus .alpha.-amylase has a Histidine at position corresponding to K446 in SP722. Therefore, for said a-amylases these substitutions are not relevant.

[0097] As can been seen from the alignment in FIG. 1 the B. licheniformis .alpha.-amylase, the B. amyloliquefaciens .alpha.-amylase and the B. stearothermophilus .alpha.-amylase have a Serine at position corresponding to P459 in SP722. Further, the Bacillus strain 12512.alpha.-amylase has a Threonine at position corresponding to P459 in SP722. Therefore, for said .alpha.-amylases these substitutions are not relevant.

Stabilization of Enzymes Having High Activity at Medium Temperatures.

[0098] In a further embodiment, the invention relates to improving the stability of low temperature .alpha.-amylases (e.g., Alteromonas haloplanctis (Feller et al., (1994), Eur. J. Biochem 222:441-447), and medium temperature .alpha.-amylases (e.g., SP722 and SP690) possessing medium temperature activity, i.e., commonly known as psychrophilic enzymes and mesophilic enzymes. The stability can for this particular enzyme class be understood either as thermostability or the stability at Calcium depletion conditions.

[0099] Typically, enzymes displaying the high activity at medium temperatures also display severe problems under conditions that stress the enzyme, such as temperature or Calcium depletion.

[0100] Consequently, the objective is to provide enzymes that at the same time display the desired high activity at medium temperatures without loosing their activity under slightly stressed conditions.

[0101] The activity of the stabilized variant measured at medium temperatures should preferably be between 100% or more and 50%, and more preferably between 100% or more and 70%, and most preferably between 100% or more and 85% of the original activity at that specific temperature before stabilization of the enzyme and the resulting enzyme should withstand longer incubation at stressed condition than the wild type enzyme.

[0102] Contemplated enzymes include .alpha.-amylases of, e.g., bacterial or fungal origin.

[0103] An example of such a low temperature .alpha.-amylase is the one isolated from Alteromonas haloplanctis (Feller et. al., (1994), Eur. J. Biochem 222:441-447). The crystal structure of this alpha-amylase has been solved (Aghajari et al., (1998), Protein Science 7:564-572).

[0104] The A. haloplanctis alpha-amylase (5 in alignment shown in FIG. 4) has a homology of approximately 66% to porcine pancreatic alpha-amylase (PPA) (3 in the alignment shown in FIG. 4). The PPA 3D structure is known, and can be obtained from Brookhaven database under the name 1OSE or 1DHK. Based on the homology to other mare stable alpha amylases, stabilization of "the low temperature highly active enzyme" from Alteromonas haloplanctis alpha-amylase, can be obtained and at the same time retaining the desired high activity at medium temperatures.

[0105] FIG. 4 shown a multiple sequence alignments of five .alpha.-amylases, including the AHA and the PPA .alpha.-amylase. Specific mutations giving increased stability in Alteromoxias haloplantis alpha-amylase:

T66P, Q69P, R155P, Q177R, A205P, A232P, L243R, V295P, S315R.

Methods for Preparing .alpha.-Amylase Variants

[0106] Several methods for introducing mutations into genes are known in the art. After a brief discussion of the cloning of .alpha.-amylase-encoding DNA sequences, methods for generating mutations at specific sites within the .alpha.-amylase-encoding sequence will be discussed.

Cloning a DNA Sequence Encoding an .alpha.-AmylaseCloning a DMA, Sequence Encoding an a-AmylaseCloning a DNA Sequence Encoding an a-AmylaseCloning a DNA Sequence Encoding an a-AmylaseCloning a DNA Sequence Encoding an a-AmylaseCloning a DNA Sequence Encoding an a-AmylaseCloning a DNA Sequence Encoding an a-AmylaseCloning a DNA Sequence Encoding an a-AmylaseCloning a DNA Sequence Encoding an a-Amylase

[0107] The DNA sequence encoding a parent .alpha.-amylase may be isolated from any cell or microorganism producing the .alpha.-amylase in question, using various methods well known in the art. First, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the .alpha.-amylase to be studied. Then, if the amino acid sequence of the .alpha.-amylase is known, homologous, labeled oligonucleotide probes may be synthesized and used to identify .alpha.-amylase-encoding clones from a genomic library prepared from the organism in question. Alternatively, a labeled oligonucleotide probe containing sequences homologous to a known .alpha.-amylase gene could be used as a probe to identify .alpha.-amylase-encoding clones, using hybridisation and washing conditions of lower stringency.

[0108] Yet another method for identifying .alpha.-amylase-encoding clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming .alpha.-amylase-negative bacteria with the resulting genomic DMA library, and then plating the transformed bacteria onto agar containing a substrate for .alpha.-amylase, thereby allowing clones expressing the .alpha.-amylase to be identified.

[0109] Alternatively, the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g., the phosphoroamidite method described by S. L. Beaucage and M. H. Caruthers (1981) or the method described by Matthes et al. (1984). In the phosphoroamidite method, oligonucleotides are synthesized, e.g., in an automatic DMA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.

[0110] Finally, the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in U.S. Pat. No. 4,683,202 or R. K. Saiki et al. (1988).

Expression of .alpha.-Amylase Variants

[0111] According to the invention, a DNA sequence encoding the variant produced by methods described above, or by any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

[0112] The recombinant expression vector carrying the DNA sequence encoding an .alpha.-amylase variant of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, a bacteriophage or an extrachromosomal element, minichromosome or an artificial chromosome. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

[0113] In the vector, the DNA sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA sequence encoding an .alpha.-amylase variant of the invention, especially in a bacterial host, are the promoter of the lac operon of E. coli, the Streptomyces coelicolor agarase gene dagA promoters, the promoters of the Bacillus licheniformis .alpha.-amylase gene (amyL), the promoters of the Bacillus stearothermophilus maltogenic amylase gene (amyM), the promoters of the Bacillus amyloliquefaciens .alpha.-amylase (amyQ), the promoters of the Bacillus subtilis xylA and xylB genes etc. For transcription in a fungal host, examples of useful promoters are those derived from the gene encoding A, oryzae TAKA amylase, Rhizomucor miehei aspartie proteinase, A. niger neutral .alpha.-amylase, A. niger acid stable .alpha.-amylase, A. niger glucoamylase, Rhizomucor miehei lipase, A. oryzae alkaline protease, A. oryzae triose phosphate isomerase or A. nidulans acetamidase.

[0114] The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, poly-adenylation sequences operably connected to the DNA sequence encoding the .alpha.-amylase variant, of the invention. Termination and polyadenyiation sequences may suitably be derived from the same sources as the promoter.

[0115] The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pJJ702.

[0116] The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the dal genes from B. subtilis or B. licheniformis, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Furthermore, the vector may comprise Aspergillus selection markers such as amdS, argB, niaD and sC, a marker giving rise to hygromycin resistance, or the selection may be accomplished by cotransformation, e.g., as described in WO 91/17243.

[0117] While intracellular expression may be advantageous in some respects, e.g., when using certain bacteria as host cells, it is generally preferred that the expression is extracellular. In general, the Bacillus .alpha.-amylases mentioned herein comprise a pre-region permitting secretion of the expressed protease into the culture medium. If desirable, this preregion may be replaced by a different preregion or signal sequence, conveniently accomplished by substitution of the DNA sequences encoding the respective preregions.

[0118] The procedures used to ligate the DNA construct of the invention encoding an .alpha.-amylase variant, the promoter, terminator and other elements, respectively, and to insert, them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989).

[0119] The cell of the invention, either comprising a DNA construct or an expression vector of the invention as defined above, is advantageously used as a host cell in the recombinant production of an .alpha.-amylase variant of the invention. The cell may be transformed with the DNA construct of the invention encoding the variant, conveniently by integrating the DMA construct (in one or more copies) in the host chromosome. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g., by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.

[0120] The cell of the invention may be a cell of a higher organism such as a mammal or an insect, but is preferably a microbial cell, e.g. a bacterial or a fungal (including yeast) cell.

[0121] Examples of suitable bacteria are Gram positive bacteria such as Bacillus subtilis, Bacillus licheniformis, Bacillus lentus, Bacillus brevis, Bacillus stearothermophilus, Bacillus alkalo-philus, Bacillus amyloliquefaciens, Bacillus coagulans, Bacillus circulans, Bacillus lautus, Bacillus megaterium, Bacillus thuringiensis, or Streptomyces lividans or Streptomyces murinus, or gramnegative bacteria such as E. coli. The transformation of the bacteria may, for instance, be effected by protoplast transformation or by using competent cells in a manner known per se.

[0122] The yeast organism may favorably be selected from a species of Saccharomyces or Schizosaccharomyces, e.g. Saccharomyces cerevisiae. The filamentous fungus may advantageously belong to a species of Aspergillus, e.g., Aspergillus oryzae or Aspergillus niger. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known per se. A suitable procedure for transformation of Aspergillus host cells is described in EP 238 023.

[0123] In a yet further aspect, the present invention relates to a method of producing an .alpha.-amylase variant of the invention, which method comprises cultivating a host cell as described above under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium.

[0124] The medium used to cultivate the cells may be any conventional medium suitable for growing the host, cell in question and obtaining expression of the .alpha.-amylase variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. as described in catalogues of the American Type Culture Collection).

[0125] The .alpha.-amylase variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

INDUSTRIAL APPLICATIONS

[0126] The .alpha.-amylase variants of this invention possesses valuable properties allowing for a variety of industrial applications. In particular, enzyme variants of the invention are applicable as a component in washing, dishwashing and hard-surface cleaning detergent compositions.

[0127] Numerous variants are particularly useful in the production of sweeteners and ethanol from starch, and/or for textile desizing. Conditions for conventional starch-conversion processes, including starch liquefaction and/or saccharification processes, are described in, e.g., U.S. Pat. No. 3,912,590 and in BP patent publications Nos. 252,730 and 63,909,

Detergent Compositions

[0128] As mentioned above, variants of the invention may suitably be incorporated in detergent, compositions. Reference is made, for example, to WO 96/23874 and WO 97/07202 for further details concerning relevant ingredients of detergent compositions (such as laundry or dishwashing detergents), appropriate methods of formulating the variants in such detergent compositions, and for examples of relevant types of detergent compositions.

[0129] Detergent compositions comprising a variant of the invention may additionally comprise one or more other enzymes, such as a lipase, cutinase, protease, cellulase, peroxidase or laccase, and/or another .alpha.-amylase.

[0130] .alpha.-amylase variants of the invention may be incorporated in detergents at conventionally employed concentrations. It is at present contemplated that a variant of the invention may be incorporated in an amount corresponding to 0.00001-1 mg (calculated as pure, active enzyme protein) of .alpha.-amylase per liter of wash/dishwash liquor using conventional dosing levels of detergent.

[0131] The invention also relates to a method of providing .alpha.-amylases with 1) altered pH optimum, and/or 2) altered temperature optimum, and/or 3) improved stability, comprising the following steps:

i) identifying (a) target position(s) and/or region(s) for mutation of the .alpha.-amylase by comparing the molecular dynamics of two or more .alpha.-amylase 3D structures having substantially different pH, temperature and/or stability profiles, ii) substituting, adding and/or deleting one or more amino acids in the identified position(s) and/or region(s).

[0132] In embodiment of the invention a medium temperature .alpha.-amylase is compared with a high temperature .alpha.-amylase. In another embodiment a low temperature .alpha.-amylase is compared with either a medium or a high temperature .alpha.-amylase.

[0133] The .alpha.-amylases compared should preferably be at least 70%, preferably 80%, up to 90%, such as up to 95%, especially 95% homologous with each other.

[0134] The .alpha.-amylases compared may be Termamyl-like .alpha.-amylases as defined above. In specific embodiment the .alpha.-amylases compared are the .alpha.-amylases shown in SEQ ID NO; 1 to SEQ ID NO: 8.

[0135] In another embodiment the stability profile of the .alpha.-amylases in question compared are the Ca.sup.2+ dependency profile.

Materials and Methods

Enzymes:

[0136] SP722: (SEQ ID NO: 2, available from Novo Nordisk) Termamyl.TM. (SEQ ID NO: 4, available from Novo Nordisk) SP690: (SEQ ID NO: 1, available from Novo Nordisk) Bacillus subtilis SHA273: see WO 95/10603

Plasmids

[0137] pJE1 contains the gene encoding a variant of SP722 .alpha.-amylase (SEQ ID NO: 2): vis. deletion of 6 nucleotides corresponding to amino acids D183-G184 in the mature protein. Transcription of the JE1 gene is directed from the amyL promoter. The plasmid further more contains the origin of replication and cat-gene conferring resistance towards kanamycin obtained from plasmid pUB110 (Gryczan, T J et al. (1978), J. Bact. 134:318-329).

Methods:

[0138] Construction of Library Vector pDorK101

[0139] The E. coli/Bacillus shuttle vector pDorK101 (described below) can be used to introduce mutations without expression of .alpha.-amylase in E. coli and then be modified in such way that the .alpha.-amylase is active in Bacillus. The vector was constructed as follows: The JE1 encoding gene (SP722 with the deletion of D183-G184) was inactivated in pJE1 by gene interruption in the PstI site in the 5'coding region of the SEQ ID NO: 2: SP722 by a 1.2 kb fragment containing an E. coli origin of replication. This fragment was PCR amplified from the pUC19 (GenBank Accession #:X02514) using the forward primer: 5'-gacctgcagtcaggcaacta-3' and the reverse primer: 5'-tagagtcgacctgcaggcat-3'. The PCR amplicon and the pJE1 vector were digested with PstI at 37.degree. C. for 2 hours. The pJE1 vector fragment and the PCR fragment were ligated at room temperature, for 1 hour and transformed in E. coli by electrotransformation. The resulting vector is designated pDorK101.

Filter Screening Assays

[0140] The assay can be used to screening of Termamyl-like .alpha.-amylase variants having an improved stability at high pH compared to the parent enzyme and Termamyl-like .alpha.-amylase variants having an improved stability at high pH and medium temperatures compared to the parent enzyme depending of the screening temperature setting

High pH Filter Assay

[0141] Bacillus libraries are plated on a sandwich of cellulose acetate (OE 67, Schleicher & Sehuell, Dassel, Germany)--and nitrocellulose filters (Protran-Ba 85, Schleicher & Sehuell, Dassel, Germany) on TY agar plates with 10 .mu.g/ml kanamycin at 37.degree. C. for at least 21 hours. The cellulose acetate layer is located on the TY agar plate.

[0142] Each filter sandwich is specifically marked with a needle after plating, but before incubation in order to be able to localize positive variants on the filter and the nitrocellulose filter with bound variants is transferred to a container with glycin-NaOH buffer, pH 8.6-10.6 and incubated at room temperature (can be altered from 10.degree.-60.degree. C.) for 15 min. The cellulose acetate filters with colonies are stored on the TY-plates at room temperature until use. After incubation, residual activity is detected on plates containing 1% agarose, 0.2% starch in glycin-NaOH buffer, pH 8.6-10.6. The assay plates with nitrocellulose filters are marked the same way as the filter sandwich and incubated for 2 hours, at room temperature. After removal of the filters the assay plates are stained with 10% Lugol solution. Starch degrading variants are detected as white spots on dark blue background and then identified on the storage plates. Positive variants are rescreened twice under the same conditions as the first screen.

Low Calcium Filter Assay

[0143] The Bacillus library are plated on a sandwich of cellulose acetate (OE 67, Schleicher & Schuell, Dassel, Germany)--and nitrocellulose filters (Protran-Ba 85, Schleicher & Schuell, Dassel, Germany) on TY agar plates with a relevant antibiotic, e.g., kanatnycin or chloramphenicol, at 37.degree. C. for at least 21 hours. The cellulose acetate layer is located on the TY agar plate.

[0144] Each filter sandwich is specifically marked with a needle after plating, but before incubation in order to be able to localize positive variants on the filter and the nitrocellulose filter with bound variants is transferred to a container with carbonate/bicarbonate buffer pH 8.5-10 and with different EDTA concentrations (0.001 mM-100 mM). The filters are incubated at room temperature for 1 hour. The cellulose acetate filters with colonies are stored on the TY-plates at room temperature until use. After incubation, residual activity is detected on plates containing 1% agarose, 0.2% starch in carbonate/bicarbonate buffer pH 8.5-10. The assay plates with nitrocellulose filters are marked the same way as the filter sandwich and incubated for 2 hours, at room temperature. After removal of the filters the assay plates are stained with 10% Lugol solution. Starch degrading variants are detected as white spots on dark blue background and then identified on the storage plates. Positive variants are rescreened twice under the same conditions as the first screen.

Method to Obtaining the Regions of Interest:

[0145] There are three known 3D structures of bacterial .alpha.-amylases. Two of B. licheniformis .alpha.-amylase, Brookhaven database 1BPL (Machius et al. (1995), J. Mol. Biol. 246, p. 545-559) and 1VJS (Song et al. (1996), Enzymes for Carbohydrate 163 Engineering (Prog. Biotechnol. V 12). These two structures are lacking an important piece of the structure from the so-called B-domain, in the area around the two Calcium ions and one Sodium ion binding sites. We have therefore used a 3D structure of an .alpha.-amylase BA2 (WO 96/23874 which are a hybrid between BAN.TM. (SEQ ID NO, 5) and B. licheniformis .alpha.-amylase (SEQ ID NO. 4). On basis of the structure a model of B. licheniformis alpha amylase and the SP722.alpha.-amylase has been build.

Fermentation and Purification of .alpha.-amylase Variants

[0146] Fermentation and purification may be performed by methods well known in the art.

Stability Determination

[0147] All stability trials are made using the same set up. The method are:

The enzyme is incubated under the relevant conditions (1-4). Samples are taken at various time points, e.g., after 0, 5, 10, 15 and 30 minutes and diluted 2 5 times (same dilution for all taken samples) in assay buffer (0.1M 50 mM Britton buffer pH 7.3) and the activity is measured using the Phadebas assay (Pharmacia) under standard conditions pH 7.3, 37.degree. C.

[0148] The activity measured before incubation (0 minutes) is used as reference (100%). The decline in percent is calculated as a function of the incubation time. The table shows the residual activity after, e.g., 30 minutes of incubation.

Specific Activity Determination

[0149] The specific activity is determined using the Phadebas assay (Pharmacia) as activity/mg enzyme. The manufactures instructions are followed (see also below under "Assay for .alpha.-amylase activity).

Assays for .alpha.-Amylase Activity

1. Phadebas Assay

[0150] .alpha.-amylase activity is determined by a method employing Phadebas.RTM. tablets as substrate. Phadebas tablets (Phadebas.RTM. Amylase Test, supplied by Pharmacia Diagnostic) contain a cross-linked insoluble blue-colored starch polymer which has been mixed with bovine serum albumin and a buffer substance and tabletted.

[0151] For every single measurement one tablet is suspended in a tube containing 5 ml 50 mM Britton-Robinson buffer (50 mM acetic acid, 50 mM phosphoric acid, 50 mM boric acid, 0.1 mM CaCl.sub.2, pH adjusted to the value of interest with NaOH). The test is performed in a water bath at the temperature of interest. The .alpha.-amylase to be tested is diluted in x ml of 50 mM Britton-Robinson buffer. 1 ml of this .alpha.-amylase solution is added to the 5 ml 50 mM Britton-Robinson buffer. The starch is hydrolyzed by the .alpha.-amylase giving soluble blue fragments. The absorbance of the resulting blue solution, measured spectrophotometrically at 620 nm, is a function of the .alpha.-amylase activity.

[0152] It is important that the measured 620 nm absorbance after 10or 15 minutes of incubation (testing time) is in the range of 0.2 to 2.0 absorbance units at 620 nm. In this absorbance range there is linearity between activity and absorbance (Lambert-Beer law). The dilution of the enzyme must therefore be adjusted to fit this criterion. Under a specified set of conditions (temp., pH, reaction time, buffer conditions) 1 trig of a given .alpha.-amylase will hydrolyze a certain amount of substrate and a blue colour will be produced. The colour intensity is measured at 620 nm. The measured absorbance is directly proportional to the specific activity (activity/mg of pure .alpha.-amylase protein) of the .alpha.-amylase in question under the given set of conditions.

2. Alternative Method

[0153] .alpha.-amylase activity is determined by a method employing the PNP-G7 substrate. PNP-G7 which is a abbreviation for p nitrophenyl-.alpha.,D-maltoheptaoside is a blocked oligosaccharide which can be cleaved by an endo-amylase. Following the cleavage, the .alpha.-Glucosidase included in the kit digest the substrate to liberate a free PNP molecule which has a yellow colour and thus can be measured by visible spectophometry at .lamda.=405 nm. (400-420 nm.). Kits containing PNP-G7 substrate and .alpha.-Glucosidase is manufactured by Boehringer-Mannheim, (cat.No. 1054635).

[0154] To prepare the substrate one bottle of substrate (BM 1442309) is added to 5 ml buffer (BM1442309). To prepare the .alpha.-Glucosidase one bottle of .alpha.-Glueosidase (BM 1462309) is added to 45 ml buffer (BM1442309). The working solution is made by mixing 5 ml .alpha.-Glucosidase solution with 0.5 ml substrate.

[0155] The assay is performed by transforming 20 .mu.l enzyme solution to a 96 well microtitre plate and incubating at 25.degree. C. 200 .mu.l working solution, 25.degree. C. is added. The solution is mixed and pre-incubated 1 minute and absorption is measured every 15 sec. over 3 minutes at OD 405 nm.

[0156] The slope of the time dependent absorption-curve is directly proportional to the specific activity (activity per rag enzyme) of the .alpha.-amylase in question under the given set of conditions.

General Method for Random Mutagenesis by Use of the DOPE Program

[0157] The random mutagenesis may be carried out by the following steps:

1. Select regions of interest for modification in the parent enzyme 2. Decide on mutation sites and non-mutated sites in the selected region 3. Decide on which kind of mutations should be carried out, e.g. with respect to the desired stability and/or performance of the variant to be constructed 4. Select structurally reasonable mutations. 5. Adjust the residues selected by step 3 with regard to step 4. 6. Analyze by use of a suitable dope algorithm the nucleotide distribution. 7. If necessary, adjust the wanted residues to genetic code realism (e.g., taking into account constraints resulting from the genetic code (e.g. in order to avoid introduction of stop codons))(the skilled person will be aware that some codon combinations cannot be used in practice and will need to be adapted) 8. Make primers 9. Perform random mutagenesis by use of the primers 10. Select resulting .alpha.-amylase variants by screening for the desired improved properties.

[0158] Suitable dope algorithms for use in step 6 are well known in the art. One algorithm is described by Tomandl, D, et al., Journal of Computer-Aided Molecular Design, 11 (1997), pp. 29-38). Another algorithm, DOPE, is described in the following:

The Dope Program

[0159] The "DOPE" program is a computer algorithm useful to optimize the nucleotide composition of a codon triplet in such a way that it encodes an amino acid distribution which resembles most the wanted amino acid distribution. In order to assess which of the possible distributions is the most similar to the wanted amino acid distribution, a scoring function is needed. In the "Dope" program the following function was found to be suited:

s .ident. i = 1 N ( x i yi ( 1 - x i ) 1 - y i y i yi ( 1 - y i ) 1 - y i ) w i , ##EQU00001##

where the x.sub.i's are the obtained amounts of amino acids and groups of amino acids as calculated by the program, y.sub.i's are the wanted amounts of amino acids and groups of amino acids as defined by the user of the program (e.g. specify which of the 20 amino acids or stop codons are wanted to be introduced, e.g. with a certain percentage (e.g. 90% Ala, 3% Ile, 7% Val), and w.sub.i's are assigned weight factors as defined by the user of the program (e.g., depending on the importance of having a specific amino acid residue inserted into the position in question). N is 21 plus the number of amino acid groups as defined by the user of the program. For purposes of this function 0.degree. is defined as being 1.

[0160] A Monte-Carlo algorithm (one example being the one described by Valleau, J. P. & Whittington, S. G. (1977) A guide to Mont Carlo for statistical mechanics; 1 Highways. In "Stastistieal Mechanics, Part A" Equilibrium Techniqeues ed. B. J. Berne, New York: Plenum) is used for finding the maximum value of this function. In each Iteration the following steps are performed: [0161] 1. A new random nucleotide composition is chosen for each base, where the absolute difference between the current and the new composition is smaller than or equal to d for each of the four nucleotides G,A,T,C in all three positions of the codon (see below for definition of d). [0162] 2. The scores of the new composition and the current composition are compared by the use of the function s as described above. If the new score is higher or equal to the score of the current composition, the new composition is kept and the current composition is changed to the new one. If the new score is smaller, the probability of keeping the new composition is exp(1000)(new_score-current_score)).

[0163] A cycle normally consists of 1000 Iterations as described above in which d is decreasing linearly from 1 to 0. One hundred or more cycles are performed in an optimization process. The nucleotide composition resulting in the highest score is finally presented.

EXAMPLES

Example 1

Example on Homology Building of Termamyl.TM.

[0164] The overall homology of the B. licheniformis .alpha.-amylase (in the following referred to as Termamyl.TM.) to other Termamyl-like .alpha.-amylases is high and the percent similarity is extremely high. The similarity calculated for Termamyl.TM. to BSG (the B. stearothermophilus .alpha.-amylase having SEQ ID NO: 3), and BAN (the B. amyloliquefaciens .alpha.-amylase having SEQ ID NO: 5) using the University of Wisconsin Genetics Computer Group's program GCG gave 89% and 78%, respectively. TERM has a deletion of 2 residues between residue G180 and K181 compared to BAN.TM. and BSG. BSG has a deletion of 3 residues between G371 and 1372 in comparison with BAN.TM. and Termamyl.TM.. Further BSG has a C-terminal extension of more than 20 residues compared to BAN.TM. and Termamyl.TM.. BAN.TM. has 2 residues less and Termamyl has one residue less in the N-terminal compared to BSG.

[0165] The structure of the B. licheniformis (Termamyl.TM.) and of the B. amyloliquefaciens .alpha.-amylase (BAN.TM.), respectively, was model built on the structure disclosed in Appendix 1 of WO 96/23974. The structure of other Termamyl-like .alpha.-amylases (e.g. those disclosed herein) may be built analogously.

[0166] In comparison with the .alpha.-amylase used for elucidating the present structure, Termamyl.TM. differs in that it lacks two residues around 178-182. In order to compensate for this in the model structure, the HOMOLOGY program from BIOSYM was used to substitute the residues in equivalent positions in the structure (not only structurally conserved regions) except for the deletion point. A peptide bond was established between G179(G177) and K180(K180) in Termamyl.TM. (BAN.TM.), The close structural relationship between the solved structure and the model structure (and thus the validity of the latter) is indicated by the presence of only very few atoms found to be too close together in the model.

[0167] To this very rough structure of Termamyl.TM.was then added all waters (605) and ions (4 Calcium and 1 Sodium) from the solved structure (See Appendix 1 of WO 96/23874) at the same coordinates as for said solved structure using the INSIGHT program. This could be done with only few overlaps--in other words with a very nice fit. This model structure were then minimized using 200 steps of Steepest descent and 600 steps of Conjugated gradient (see Brooks et al 1983, J. Computational Chemistry 4, p. 187-217). The minimized structure was then subjected to molecular dynamics, Bps heating followed by up to 200 ps equilibration but more than 3 Bps. The dynamics as run with the Verlet algorithm and the e-quilibration temperature 300K were kept using the Behrendsen coupling to a water bath (Berendsen et. al., 1984, J. Chemical Physics 81, p. 3684-3690). Rotations and translations were removed every pico second.

Example 2

Method of Extracting Important Regions for Identifying .alpha.-Amylase Variants with Improved pH Stability and Altered Temperature Activity

[0168] The X-ray structure and/or the model build structure of the enzyme of interest, here SP722 and Termamyl.TM. are subjected to molecular dynamics simulations. The molecular dynamics simulation are made using the CHARMM (from Molecular simulations (MSI)) program or other suited program like, e.g., DISCOVER (from MSI). The molecular dynamic analysis is made in vacuum, or more preferred including crystal waters, or with the enzyme embedded in water, e.g., a water sphere or a water box. The simulation are run for 300 pico seconds (ps) or more, e.g., 300-1200 ps. The isotropic fluctuations are extracted for the CA carbons of the structures and compared between the structures. Where the sequence has deletions and/or insertions the isotropic fluctuations from the other structure are inserted thus giving 0 as difference in isotropic fluctuation. For explanation of isotropic fluctuations see the CHARMM manual (obtainable from MSI).

[0169] The molecular dynamics simulation can be done using standard charges on the chargeable amino acids. This is Asp and Glu are negatively charged and Lys and Arg are positively charged. This condition resembles the medium pH of approximately 7. To analyze a higher or lower pH, titration of the molecule can be done to obtain the altered pKa's of the standard titrateable residues normally within pH 2-10; Lys, Arg, Asp, Glu, Tyr and His. Also Ser, Thr and Cys are titrateable but are not taking into account here. Here the altered charges due to the pH has been described as both Asp and Glu are negative at high pH, and both Arg and Lys are uncharged. This imitates a pH around 10 to 11 where the titration of Lys and Arg starts, as the normal pKa of these residues are around 9-11.

[0170] 1. The approach used for extracting important regions for identifying .alpha.-amylase variants with high pH stability:

[0171] The important regions for constructing variants with improved pH stability are the regions which at the extreme pH display the highest mobility, i.e., regions having the highest isotropic fluctuations.

[0172] Such regions are identified by carrying out two molecular dynamics simulations; i) a high pH run at which the basic amino acids, Lys and Arg, are seen as neutral (i.e. not protonated) and the acidic amino acids, Asp and Glu, have the charge (-1) and ii) a neutral pH run with the basic amino acids, Lys and Arg, having the net charge of (+1) and the acidic amino acids having a charge of (-1).

[0173] The two run are compared and regions displaying the relatively higher mobility at high pH compared to neutral pH analysis were identified.

[0174] Introduction of residues improving general stability, e.g., hydrogen bonding, making the region more rigid (by mutations such as Proline substitutions or replacement of Glycine residues), or improving the charges or their interaction, improves the high pH stability of the enzyme.

[0175] 2. The approach used for extracting regions for identifying .alpha.-amylase variants with increased activity at medium temperatures:

[0176] The important regions for constructing variants with increased activity at medium temperature was found as the difference between the isotropic fluctuations in SP722 and Termamyl, i.e., SP722 minus Termamyl CA isotrophic fluctuations, The regions with the highest mobility in the isotrophic fluctuations were selected. These regions and there residues were expected to increase the activity at medium temperatures. The activity of an alpha-amylase is only expressed if the correct mobility of certain residues are present. If the mobility of the residues is too low the activity is decreased or abandoned.

Example 3

Construction, by Localized Random, Doped Mutagenesis, of Termamyl-Like .alpha.-Amylase Variants having an Improved Ca2+ Stability at Medium Temperatures Compared to the Parent Enzymes

[0177] To improve the stability at low calcium concentration of .alpha.-amylases random mutagenesis in pre-selected region was performed.

Region: Residue:

SAT: R181-W189

[0178] The DOPE software (see Materials and Methods) was used to determine spiked codons for each suggested change in the SA1 region minimizing the amount of stop codons (see table 1). The exact, distribution of nucleotides was calculated in the three positions of the codon to give the suggested population of amino acid changes. The doped regions were doped specifically in the indicated positions to have a high chance of getting the desired residues, but still allow other possibilities.

TABLE-US-00006 TABLE 1 Distribution of amino acid residues for each position R181: 72% R, 2% N, 7% Q, 4% H, 4% K, 11% S G182: 73% G, 13% A, 12% S, 2% T K185: 95% K, 5% R A186: 50% A, 4% N, 6% D, 1% E, 1% G, 1% K, 5% S, 31% T W187: 100% W D188: 100% D W189: 92% W, 8% S

[0179] The resulting doped oligonucleotide strand is shown in table 2 as sense strand: with the wild type nucleotide and amino acid sequences and the distribution of nucleotides for each doped position.

TABLE-US-00007 TABLE 2 Position 181 182 185 186 187 188 189 Amino acid seq. Arg Gly Lys Ala Thr Asp Thr Wt nuc. seq. cga ggt aaa gct tgg gat tgg Forward primer: (SEQ ID NO: 15) FSA: 5'-caa aat cgt atc tac aaa ttc 123 456 a7g 8910 tgg gat t11g gaa gta gat tcg gaa aat-3' Distribution of nucleotides for each doped Position 1: 35% A, 65% C 2: 83% G, 17% A 3: 63% G, 37% T 4: 86% G, 14% A 5: 85% G, 15% C 6: 50% T, 50% C 7: 95% A, 5%G 8: 58% G, 37% A, 5% T 9: 86% C, 13% A, 1% G 10: 33% T, 17% G 11: 92% G, 8% C Reverse primer: (SEQ ID NO: 16) RSA: 5'-gaa ttt gta gat acg att ttg-3'

Random Mutagenesis

[0180] The spiked oligonucleotides apparent from Table 2 (which by a common term is designated FSA) and reverse primers RSA for the SA1 region and specific SEQ ID NO: 2: SP722 primers covering the SacII and the Drain sites are used to generate PGR-library-fragments by the overlap extension method (Horton et al., Gene, 77 (1989), pp. 61-68) with an overlap of 21 base pairs. Plasmid pJE1 is template for the Polymerase Chain Reaction. The PGR fragments are cloned in the E. coli/Bacillus shuttle vector pDork101 (see Materials and Methods) enabling mutagenesis in E. coli and immediate expression in Bacillus subtilis preventing lethal accumulation of amylases in E. coli. After establishing the cloned PCR fragments in E. coli, a modified pUC19 fragment is digested out of the plasmid and the promoter and the mutated Termamyl gene is physically connected and expression can take place in Bacillus.

Screening

[0181] The library may be screened in the low calcium filter assays described in the "Material and Methods" section above.

Example 4

Construction of Variants of Amylase SEQ ID NO: 1 (SP690)

[0182] The gene encoding the amylase from SEQ ID NO; 1 is located in a plasmid pTVB106 described in WO96/23873. The amylase is expressed from the amyL promoter in this construct in Bacillus subtilis.

[0183] A variant of the protein is delta(T183-G184)+Y243F+Q3 91E+K444Q. Construction of this variant is described in WO96/23873.

[0184] Construction of delta(T183-G184)+N195F by the mega-primer method as described by Sarkar and Sommer, (1990), BioTechniques 8: 404-407.

[0185] Gene specific primer B1 (SEQ ID NO: 17) and mutagenic primer 101458 (SEQ ID NO: 19) were used to amplify by PCR an approximately 645 bp DNA fragment from a pTVB106-like plasmid (with the delta(T183-G184) mutations in the gene encoding the amylase from SEQ ID NO: 1).

[0186] The 645 bp fragment was purified from an agarose gel and used as a mega-primer together with primer Y2 (SEQ ID NO: 18) in a second PCR carried out on the same template.

[0187] The resulting approximately 1080 bp fragment was digested with restriction enzymes BstEII and AflIII and the resulting approximately 510 bp DNA fragment was purified and ligated with the pTVB106-like plasmid (with the delta (T183-G184) mutations in the gene encoding the amylase from SEQ ID NO: 1) digested with the same enzymes. Competent Bacillus subtilis SHA273 (amylase and protease low) cells were transformed with the ligation and Chlorampenicol resistant transformants and was checked by DNA sequencing to verify the presence of the correct mutations on the plasmid.

TABLE-US-00008 primer B1: (SEQ ID NO: 17) 5' CGA TTG CTG ACG CTG TTA TTT GCG 3' primer Y2: (SEQ ID NO: 18) 5' CTT GTT CCC TTG TCA GAA CCA ATG 3' primer 101458 (SEQ ID NO: 19): 5' GT CAT AGT TGC CGA AAT CTG TAT CGA CTT C 3'

[0188] The construction of variant: delta(T183-G184)+K185R+A186T was carried out in a similar way except that mutagenic primer 101638 was used.

TABLE-US-00009 primer 101638: (SEQ ID NO: 20) 5' CC CAG TCC CAC GTA CGT CCC CTG AAT TTA TAT ATT TTG 3'

[0189] Variants: delta(T183-G184)+A186T, delta(T183-G184)+A186I, delta(T183-G184)+A186S, delta(T183-G184)+A186N are constructed by a similar method except that pTVB106-like plasmid (carrying variant delta(T183-G184)+K185R+A186T) is used as template and as the vector for the cloning purpose. The mutagenic oligonucleotide (Oligo 1) is:

TABLE-US-00010 (SEQ ID NO: 21) 5' CC CAG TCC CAG NTCTTT CCC CTG AAT TTA TAT ATT TTG 3'

[0190] N represents a mixture of the four bases: A, C, G, and T used in the synthesis of the mutagenicoli-gonucleotide.

Sequencing of Transformants Identifies the Correct Codon for Amino Acid Position 186 in the Mature Amylase.

[0191] variant: delta(T183-G184)+K185R+A186T+N195F is constructed as follows:

PGR is carried out with primer x2 (SEQ ID NO: 22) and primer 101458 (SEQ ID NO: 19) on pTVB106-like plasmid (with mutations delta(T183-G184)+K185R+A186T). The resulting DNA fragment is used as a mega-primer together with primer Y2 (SEQ ID NO: 18) in a PGR on pTVB106-like plasmid (with mutations delta(T183-G184)+N195). The product of the second PGR is digested with restriction endonucleases Acc651 and AflIII and cloned into pTVB106 like plasmid (delta(T183-G184)+N195F) digested with the same enzymes.

TABLE-US-00011 primer x2: (SEQ ID NO: 22) 5' GCG TGG ACA AAG TTT GAT TTT CCT G 3'

[0192] Variant: delta(T183-G184)+K185R+A186T+N195F+Y243F+Q391E+K444Q is constructed as follows:

[0193] PGR is carried out with primer x2 and primer 101458 on pTVB106-like plasmid (with mutations delta(T183-G184)+K185R+A186T). The resulting DNA fragment is used as a mega-primer together with primer Y2 in a PGR on pTVB106 like plasmid (with mutations delta(T183-G184)+Y243F+Q39TE+K444Q). The product of the second PGR is digested with restriction endonucleases Acc65I and AflIII and cloned into pTVB106 like plasmid (delta(T183-G184)+Y243F+Q391E+K444Q) digested with the same enzymes.

Example 5

Construction of Site-Directed .alpha.-Amylase Variants in the Parent SP722 .alpha.-Amylase (SEQ ID NO: 2)

[0194] Construction of variants of amylase SEQ ID NO: 2 (SP722) is carried out as described below.

[0195] The gene encoding the amylase from SEQ ID NO: 2 is located in a plasmid pTVB112 described in WO 96/23873. The amylase is expressed from the amyL promoter in this construct in Bacillus subtilis.

[0196] Construction of delta(D183-G184)+V56I by the mega-primer method as described by Sarkar and Sommer, 1990 (BioTechniques 8: 404-407).

[0197] Gene specific primer DAQ3 and mutagenic primer DA07 are used to amplify by PGR an approximately 820 bp DNA fragment from a pTVB112-like plasmid (with the delta(D183-G184) mutations in the gene encoding the .alpha.-amylase shown in SEQ ID NO: 2.

[0198] The 820 bp fragment is purified from an agarose gel and used as a mega-primer together with primer DA01 in a second PGR carried out on the same template.

[0199] The resulting approximately 920 bp fragment is digested with restriction enzymes NgoM I and Aat II and the resulting approximately 170 bp DNA fragment is purified and ligated with the pTVB112-like plasmid (with the delta(D183-G184) mutations in the gene encoding the amylase shown in SEQ ID NO: 2) digested with the same enzymes. Competent Bacillus subtilis SHA273 (amylase and protease low) cells are transformed with the ligation and Chlorampenicol resistant transformants are checked by DNA sequencing to verify the presence of the correct mutations on the plasmid.

TABLE-US-00012 primer DA01: (SEQ ID NO: 22) 5' CCTAATGATGGGAATCACTGG 3' primer DA03: (SEQ ID NO: 24) 5' GCATTGGATGCTTTTGAACAACCG 3' primer DA07 (SEQ ID NO: 25): 5' CGCAAAATGATATCGGGTATGGAGCC 3'

Variants: delta(D183-G184)+K108L, delta(D183-G184)+K108Q, delta(D183-G184)+K108E, delta(D183-G184)+K108V, were constructed by the mega-primer method as described by Sarkar and Sommer, 1990 (BioTechniques 8; 404-407):

[0200] PCR is carried out with primer DA03 and mutagenesis primer DA20 on pTVB112-like plasmid (with mutations delta(D183-G184)). The resulting DNA fragment is used as a mega-primer together with primer DA01 in a PCR on pTVB112-like plasmid (with mutations delta(D183-G184)). The approximately 920 bp product of the second PCR is digested with restriction endonucleases Aat II and Mlu I and cloned into pTVB112-like plasmid (delta(D183-G1845) digested with the same enzymes,

TABLE-US-00013 primer DA20 (SQ ID NO: 26): 5' GTGATGAACCACSWAGGTGGAGCTGATGC 3'

[0201] S represents a mixture of the two bases: C and G used in the synthesis of the mutagenic oligonucleotide and W represents a mixture of the two bases: A and T used in the synthesis of the mutagenic oligonucleotide.

[0202] Sequencing of transformants identifies the correct codon for amino acid position 108 in the mature amylase.

[0203] Construction of the variants; delta(D183-G184)+D168A, delta(D183-G184)+D168I, delta(D183-G184)+D168V, delta(D183-G184)+D168T is carried out in a similar way except that mutagenic primer DA14 is used.

TABLE-US-00014 primer DA14 (SEQ ID NO: 27): 5' GATGGTGTATGGRYCAATCACGACAATTCC 3'

[0204] R represents a mixture of the two bases; A and G used in the synthesis of the mutagenic oligonucleotide and Y represents a mixture of the two bases; C and T used in the synthesis of the mutagenic oligonucleotide.

[0205] Sequencing of transformants identifies the correct codon for amino acid position 168 in the mature amylase.

[0206] Construction of the variant: delta(D183-G184)+Q169N is carried out in a similar way except that mutagenic primer DA15 is used.

TABLE-US-00015 primer DA15 (SEQ ID NO: 28): 5' GGTGTATGGGATAACTCACGACAATTCC 3'

[0207] Construction of the variant; delta(D183-G184)+Q169L is carried out in a similar way except that mutagenic primer DA16 is used.

TABLE-US-00016 primer DA16 (SEQ ID NO: 29): 5' GGTGTATGGGATCTCTCACGACAATTCC 3'

[0208] Construction of the variant; delta(D183-G184)+Q172N is carried out in a similar way except that mutagenic primer DA17 is used.

TABLE-US-00017 primer DA17 (SEQ ID NO: 30): 5' GGGATCAATCACGAAATTTCCAAAATCGTATC 3'

[0209] Construction of the variant: delta(D183-G184)+Q172L is carried out in a similar way except that mutagenic primer DAIS is used.

TABLE-US-00018 primer DA18 (SEQ ID NO: 31): 5' GGGATCAATCACGACTCTTCCAAAATCGTATC 3'

[0210] Construction of the variant: delta(D183-G184)+L201I is carried out in a similar way except that mutagenic primer DA06 is used.

TABLE-US-00019 primer DA06 (SEQ ID NO: 32): 5' GGAAATTATGATTATATCATGTATGCAGATGTAG 3'

[0211] Construction of the variant: delta(D183-G184)+K269S is carried out in a similar way except that mutagenic primer DA09 is used.

TABLE-US-00020 primer DA09 (SEQ ID NO: 33): 5' GCTGAATTTTGGTCGAATGATTTAGGTGCC 3'

[0212] Construction of the variant; delta(D183-G184)+K269Q is carried out in a similar way except that mutagenic primer DA11 is used.

TABLE-US-00021 primer DA11 (SEQ ID NO: 34): 5' GCTGAATTTTGGTCGAATGATTTAGGTGCC 3'

[0213] Construction of the variant; delta(D183-G184)+N270Y is carried out in a similar way except that mutagenic primer DA21 is used.

TABLE-US-00022 primer DA21 (SEQ ID NO: 35): 5' GAATTTTGGAAGTACGATTTAGGTCGG 3'

[0214] Construction of the variants: delta(D183-G184)+L272A, delta(D183-G184)+L272I, delta(D183-G184)+L272V, delta(D183-G184)+L272T is carried out in a similar way except that mutagenic primer DA12 is used,

TABLE-US-00023 primer DA12 (SEQ ID NO: 36): 5' GGAAAAACGATRYCGGTGCCTTGGAGAAC 3'

R represents a mixture of the two bases: A and G used in the synthesis of the mutagenic oligonucleotide and Y represents a mixture of the two bases: C and T used in the synthesis of the mutagenic oligonucleotide. Sequencing of transformants identifies the correct codon for amino acid position 272 in the mature amylase.

[0215] Construction of the variants: delta(D183-G184)+L275A, delta(D183-G184)+L275I, delta(D183-G184)+L275V, delta(D183-G184)+L275T is carried out in a similar way except that mutagenic primer DA13 is used.

TABLE-US-00024 primer DA13 (SEQ ID NO: 37): 5' GATTTAGGTGCCTRYCAGAACTATTTA 3'

R represents a mixture of the two bases; A and G used in the synthesis of the mutagenic oligonucleotide and Y represents a mixture of the two bases; C and T used in the synthesis of the mutagenic oligonucleotide. Sequencing of transformants identifies the correct codon for amino acid position 275 in the mature amylase.

[0216] Construction of the variant: delta(D183-G184)+Y295E is carried out In a similar way except that mutagenic primer DA08 is used.

TABLE-US-00025 primer DA08 (SEQ ID NO: 38): 5' CCCCCTTCATGAGAATCTTTATAACG 3'

[0217] Construction of delta(D183-G184)+K446Q by the mega-primer method as described by Sarkar and Sommer, 1990 (BioTechniques 8: 404-407):

[0218] Gene specific primer DA04, annealing 214-231 bp downstream relative to the STOP-codon and mutagenic primer DA10 were used to amplify by PGR an approximately 350 bp DNA fragment from a pTVB112-like plasmid (with the delta(D183-G184) mutations in the gene encoding the amylase depicted in SEQ ID NO: 2).

[0219] The resulting DNA fragment is used as a mega-primer together with primer DA05 in a PGR on pTVB112 like plasmid (with mutations delta(D183-G184)). The app. 460 bp product of the second PGR is digested with restriction endonucleases SnaB I and Not I and cloned into pTVB112 like plasmid (delta(D183-G184)) digested with the same enzymes,

TABLE-US-00026 primer DA04 (SEQ ID NO: 39): 5' GAATCCGAACCTCATTACACATTCG 3' primer DA05 (SEQ ID NO: 40) 5' CGGATGGACTCGAGAAGGAAATACCACG 3' primer DA10 (SEQ ID NO: 41): 5' CGTAGGGCAAAATCAGGCCGGTCAAGTTTGG 3'

[0220] Construction of the variants: delta(D183-G184)+K458R is carried out in a similar way except that mutagenic primer DA22 is used.

TABLE-US-00027 primer DA22 (SEQ ID NO: 42): 5' CATAACTGGAAATCGCCCGGGAACAGTTACG 3'

[0221] Construction of the variants: delta(D183-G184)+P459S and delta(D183-G184)+P459T is carried out in a similar way except that mutagenic primer DA19 is used.

TABLE-US-00028 primer DA19 (SEQ ID NO: 43): 5' CTGGAAATAAAWCCGGAACAGTTACG 3'

W represents a mixture of the two bases: A and T used in the synthesis of the mutagenic oligonucleotide. Sequencing of transformants identifies the correct codon for amino acid position 459 in the mature amylase.

[0222] Construction of the variants: delta(D183-G184)+T461P is carried out in a similar way except that mutagenic primer DA23 is used.

TABLE-US-00029 primer DA23 (SEQ ID NO: 44): 5' GGAAATAAACCAGGACCCGTTACGATCAATGC 3'

[0223] Construction of the variant: delta(D183-G184)+K142R is carried out in a similar way except that mutagenic primer DA32 is used.

TABLE-US-00030 Primer DA32 (SEQ ID NO: 45): 5' GAGGCTTGGACTAGGTTTGATTTTCCAG 3'

[0224] Construction of the variant; delta(D183-G184)+K269R is carried out in a similar way except that mutagenic primer DA31 is used.

TABLE-US-00031 Primer DA31 (SEQ ID NO: 46): 5' GCTGAATTTTGGCGCAATGATTTAGGTGCC 3'

Example 6

Construction of Site-Directed .alpha.-Amylase Variants in the Parent Termamyl .alpha.-Amylase (SEQ ID NO: 4)

[0225] The amyL gene, encoding the Termamyl .alpha.-amylase is located in plasmid pDN1528 described in WO 95/10603 (Novo Nordisk). Variants with substitutions N265R and N265D, respectively, of said parent, .alpha.-amylase are constructed by methods described in WO 97/41213 or by the "megaprimer" approach described above.

Mutagenic Oligonucleotides are:

[0226] Primer b11 for the N265R substitution:

TABLE-US-00032 (SEQ ID NO: 56) 5' PCC AGC GCG CCT AGG TCA CGC TGC CAA TAT TCA G

Primer b12 for the N265D substitution;

TABLE-US-00033 (SEQ ID NO: 57) 5' PCC AGC GCG CCT AGG TCA TCC TGC CAA TAT TCA G

P represents a phosphate group.

Example 7

Determination of pH Stability at Alkaline pH of Variants of the Parent .alpha.-Amylase having the Amino Acid Sequence Shown in SEQ ID NO: 2

[0227] In this series of analysis purified enzyme samples were used. The measurements were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5. The solutions were incubated at 75.degree. C.

[0228] After incubation for 20 and 30 min the residual activity was measured using the PNP-G7 assay (described in the "Materials and Methods" section above). The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 75.degree. C.

[0229] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO; 2) and for the variants in question.

TABLE-US-00034 Residual activity Residual activity Variant after 20 min after 30 min .DELTA.(D183-G184) + M323L 56% 44% .DELTA.(D183-G184) + M323L + R181S 67% 55% .DELTA.(D183-G184) + M323L + A186T 62% 50%

[0230] In an other series of analysis culture supernatants were used. The measurements were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5. The solutions were incubated at 80.degree. C.

[0231] After incubation for 30 minutes the residual activity was measured using the Phadebas assay (described in the "Materials and Method" section above. The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 80.degree. C.

[0232] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 2) and for the variants in question,

TABLE-US-00035 Variant Residual activity after 30 min .DELTA.(D183-G184) 4% .DELTA.(D183-G184) + P459T 25% .DELTA.(D183-G184) + K458R 31% .DELTA.(D183-G184) + K311R 10%

Example 8

Determination of Calcium Stability at Alkaline pH of Variants of the Parent .alpha.-Amylase having the Amino Acid Sequence Shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:4

A: Calcium Stability of Variants of the Sequence in SEQ ID NO: 1

[0233] The measurement were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5 to which polyphosphate was added (at time t=0) to give a final concentration of 2400 ppm. The solutions were incubated at 50.degree. C.

[0234] After incubation for 20 and 30 minutes the residual activity was measured using the PNP-G7 assay (described above). The residual activity in the samples was measured using Britton Robinson buffer pH 7.3, The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 50.degree. C.

[0235] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 1) and for the variants in question,

TABLE-US-00036 Residual activity Residual activity Variant after 20 min after 30 min .DELTA.(T183-G184) 32% 19% .DELTA.(T183-G184) + A186T 36% 23% .DELTA.(T183-G184) + K185R + A186T 45% 29% .DELTA.(T183-G184) + A186I 35% 20% .DELTA.(T183-G184) + N195F 44% n.d. n.d. = Not determinated

B: Calcium Stability of Variants of the Sequence in SEQ ID NO: 2

[0236] In this series of analysis purified samples of enzymes were used. The measurement were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5 to which polyphosphate was added (at time t=0) to give a final concentration of 2400 ppm. The solutions were incubated at 50.degree. C.

[0237] After incubation for 20 and 30 minutes the residual activity was measured using the PNP-G7 assay (described above). The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 50.degree. C.

[0238] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 2) and for the variants in question.

TABLE-US-00037 Residual activity Residual activity Variant after 20 min after 30 min .DELTA.(D183-G184) + M323L 21% 13% .DELTA.(D183-G184) + M323L + R181S 32% 19% .DELTA.(D183-G184) + M323L + A186T 28% 17% .DELTA.(D183-G184) + M323L + A186R 30% 18% .DELTA.(D183-G184) 30% 20% .DELTA.(D183-G184) + N195F 55% 44%

[0239] In this series of analysis culture supernatants were used. The measurement were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5 to which polyphosphate was added (at time t=0) to give a final concentration of 2400 ppm. The solutions were Incubated at 50.degree. C.

[0240] After incubation for 30 minutes the residual activity was measured using the Phadebas assay as described above. The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 50.degree. C.

[0241] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 2) and for the variants in question.

TABLE-US-00038 Variant Residual activity after 30 min .DELTA.(D183-G184) 0% .DELTA.(D183-G184) + P459T 19% .DELTA.(D183-G184) + K458R 18% .DELTA.(D183-G184) + T461P 13% .DELTA.(D183-G184) + E346Q + K385R 4%

C: Calcium Stability of Variants of the Sequence in SEQ ID NO: 4

[0242] The measurement were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5 to which polyphosphate was added (at time t0) to give a final concentration of 2400 ppm. The solutions were incubated at 60.degree. C. for 20 minutes.

[0243] After incubation for 20 minutes the residual activity was measured using the PNP-G7 assay (described above). The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 60.degree. C.

[0244] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 4) and for the variants in question,

TABLE-US-00039 Residual activity after Variant 20 min Termamyl (SEQ ID NO: 4) 17% N265R 28% N265D 25%

Example 9

Activity Measurement at Medium Temperature of .alpha.-Amylases having the Amino Acid Sequence Shown in SEQ ID NO: 1.

[0245] A: .alpha.-Amylase activity of Variants of the Sequence in SEQ ID NO: 1

[0246] The measurement were made using solutions of the respective variants in 50 mM Britton Robinson buffer adjusted to pH 7.3 and using the Phadebas assay described above. The activity in the samples was measured at 37.degree. C. using 50 mM Britton Robinson buffer pH 7.3 and at 25.degree. C. using 50 mM CAPS buffer pH 10.5.

[0247] The temperature dependent activity and the percentage of the activity at 25.degree. C. relative to the activity at 37.degree. C. is shown in the table below for the parent enzyme (SEQ ID NO: 1) and for the variants in question.

TABLE-US-00040 NU(25.degree. C.)/ Variant NU/mg 25.degree. C. NU/mg 37.degree. C. NU(37.degree. C.) SP690 1440 35000 4.1% .DELTA.(T183-G184) 2900 40000 7.3% .DELTA.(T183-G184) + K269S 1860 12000 15.5% .DELTA.(Q174) 3830 38000 7.9%

Another measurement was made using solutions of the respective variants in 50 mM Britton Robinson buffer adjusted to pH 7.3 and using the Phadebas assay described above. The activity in the samples was measured at 37.degree. C. and 50.degree. C. using 50 mM Britton Robinson buffer pH 7.3.

[0248] The temperature dependent activity and the percentage of the activity at 37.degree. C. relative to the activity at 50.degree. C. is shown in the table below for the parent enzyme (SEQ ID NO: 1) and for the variants in question.

TABLE-US-00041 NU(37.degree. C.)/ Variant NU/mg 37.degree. C. NU/mg 50.degree. C. NU(50.degree. C.) SP690 (seq ID NO: 1) 13090 21669 60% K269Q 7804 10063 78%

B: .alpha.Amylase Activity of Variants of the Sequence in SEQ ID NO:2

[0249] The measurement were made using solutions of the respective variants in 50 mM Britton Robinson buffer adjusted to pH 7.3 and using the Phadebas assay described above. The activity in the samples was measured at both 25.degree. C. and 37.degree. C. using 50 mM Britton Robinson buffer pH 7.3.

[0250] The temperature dependent activity and the percentage of the activity at 25.degree. C. relative to the activity at 37.degree. C. Is shown in the table below for the parent enzyme (SEQ ID NO: 2) and for the variants in question.

TABLE-US-00042 NU/mg NU/mg NU(25.degree. C.)/ Variant 25.degree. C. 37.degree. C. NU(37.degree. C.) .DELTA.(D183-G184) + M323L 3049 10202 30% .DELTA.(D183-G184) + M323L + R181S 18695 36436 51%

C: .alpha.-Amylase Activity of Variants of the Sequence in SEQ ID NO:4

[0251] The measurement were made using solutions of the respective variants in 50 mM Britton Robinson buffer adjusted to pH 7.3 and using the Phadebas assay described above. The activity in the samples was measured at both 37.degree. C. using 50 mM Britton Robinson buffer pH 7.3 and at 60.degree. C. using 50 mM CAPS buffer pH 10.5.

[0252] The temperature dependent activity and the percentage of the activity at 37.degree. C. relative to the activity at 60.degree. C. is shown in the table below for the parent enzyme (SEQ ID NO: 4) and for the variants in question.

TABLE-US-00043 Variant NU/mg 37.degree. C. NU/mg 60.degree. C. NU(37.degree. C.)/NU(60.degree. C.) Termamyl 7400 4350 170% Q264S 10000 4650 215%

Example 10

Construction of Variants of Parent Hybrid BAN:1-300/Termamyl:301-483 .alpha.-Amylase

[0253] Plasmid pTVB191 contains the gene encoding hybrid .alpha.-amylase BAN:1-300/Termamyl:301-483 as well as an origin of replication functional in Bacillus subtilis and the cat gene conferring chloramphenicol resistance.

[0254] Variant BM4 (F290E) was constructed using the megaprimer approach (Sarkar and Sommer, 1990) with plasmid pTVB191 as template.

[0255] Primer p1 (SEQ ID NO; 52) and mutagenic oligonucleotide bm4 (SEQ ID NO: 47) were used to amplify a 444 bp fragment with polymerase chain reaction (PCR) under standard conditions. This fragment was purified from an agarose gel and used as `Megaprimer` in a second PCR with primer p2 (SEQ ID NO: 5.3) resulting in a 531 bp fragment. This fragment was digested with restriction endonucleases HinDIII and Tth111I. The 389 bp fragment produced by this was ligated into plasmid pTVB191 that had been cleaved with the same two enzymes. The resulting plasmid was transformed into S. subtilis SHA273. Chloramphenicol resistant clones were selected by growing the transformants on plates containing chloramphenicol as well as insoluble starch. Clones expressing an active .alpha.-amylase were isolated by selecting clones that formed halos after staining the plates with iodine vapour. The identity of the introduced mutations was confirmed by DNA sequencing.

[0256] Variants BM5(F290K), BM6(F290A), BM8(Q360E) and BM11(N102D) were constructed in a similar way. Details of their construction are given below.

Variant: BM5(F290K)

[0257] mutagenic oligonucleotide: bm5 (SEQ ID NO: 48)

Primer (1st PGR); p1 (SEQ ID NO; 52)

[0258] Size of resulting fragment: 444 bp

Primer (2nd PCR): p2 (SEQ ID NO: 53)

[0259] Restriction endonucleases: HinDIII, Tth111I Size of cleaved fragment: 389 bp

Variant: BM6(F290A)

[0260] mutagenic oligonucleotide; bm6 (SEQ ID NO: 49)

Primer (1st PGR): p1 (SEQ ID NO: 52)

[0261] Size of resulting fragment: 444 bp

Primer (2nd PGR): p2 (SEQ ID NO: 53)

[0262] Restriction endonucleases: HinDIII, Tth111I Size of cleaved fragment: 389 bp

Variant: BM8(Q360E)

[0263] mutagenic oligonucleotide; bm8 (SEQ ID NO: 50)

Primer (1st PGR): p1 (SEQ ID NO: 52)

[0264] Size of resulting fragment; 230 bp

Primer (2nd PGR); p2 (SEQ ID NO; 53)

[0265] Restriction endonucleases: HinDIII, Tth111I Size of cleaved fragment: 389 bp

Variant: BM11(N102D)

[0266] mutagenic oligonucleotide; bm11 (SEQ ID NO; 51)

Primer (1st PGR): p3 (SEQ ID NO: 54)

[0267] Size of resulting fragment; 577

Primer (2nd PGR): p4 (SEQ ID NO: 55)

[0268] Restriction endonucleases: HinDIII, PvuI Size of cleaved fragment: 576

Mutagenic Oligonucleotides:

TABLE-US-00044 [0269] bm4 (SEQ ID NO: 47): F290E primer 5' GTG TTT GAC GTC CCG CTT CAT GAG AAT TTA CAG G bm5 (SEQ ID NO: 48): F290K primer 5' GTG TTT GAC GTC CCG CTT CAT AAG AAT TTA CAG G bm6 (SEQ ID NO: 49): F290A primer 5' GTG TTT GAC GTC CCG CTT CAT GCC AAT TTA CAG G bm8 (SEQ ID NO: 50): Q360E primer 5' AGG GAA TCC GGA TAC CCT GAG GTT TTC TAC GG bm11 (SEQ ID NO: 51): N102D primer 5' GAT GTG GTT TTG GAT CAT AAG GCC GGC GCT GAT G

Other Primers:

TABLE-US-00045 [0270] (SEQ ID N0: 52) p1: 5' CTG TTA TTA ATG CCG CCA AAC C (SEQ ID NO: 53) p2: 5' G GAA AAG AAA TGT TTA CGG TTG CG (SEQ ID NO: 54) p3: 5' G AAA TGA AGC GGA ACA TCA AAC ACG (SEQ ID NO: 55) p4: 5' GTA TGA TTT AGG AGA ATT CC

Example 11

.alpha.-Amylase Activity at Alkaline pH of Variants of BAN:1-300/Termamyl:301-483 Hybrid .alpha.-Amylase

[0271] The measurements were made using solutions for the respective enzymes and utilizing the Phadebas assay (described above). The activity was measured after incubating for 15 minutes at 30.degree. C. in 50 mM Britton-Robinson buffer adjusted to the indicated pH by NaOH,

TABLE-US-00046 NU/mg enzyme pH wt Q360E F290A F290K F290E N102D 8.0 5300 7800 8300 4200 6600 6200 9.0 1600 2700 3400 2100 1900 1900

REFERENCES CITED

[0272] Klein, C, et al., Biochemistry 1992, 31, 8740-8746, [0273] Mizuno, H., et al., J. Mol. Biol. (1993) 234, 1282-1283, [0274] Chang, C, et al, J. Mol. Biol. (1993) 229, 235-238, [0275] Larson, S. B., J. Mol. Biol. (1994) 235, 1560-1584, [0276] Lawson, C. L., J. Mol. Biol. (1994) 236, 590-600, [0277] Qian, M., et al., J. Mol. Biol. (1993) 231, 785-799, [0278] Brady, R. L., et al. Acta Crystallogr. sect. B, 47, 527-535, [0279] Swift, H. J., et al., Acta Crystallogr. sect. B, 47, 535-544 [0280] A. Kadziola, Ph.D. Thesis: "An alpha-amylase from Barley and its Complex with a Substrate Analogue Inhibitor Studied by X-ray Crystallography", Department of Chemistry University of Copenhagen 1993 [0281] MacGregor, E. A., Food Hydrocolloids, 1987, Vol. 1, No. 5-6, p. [0282] B. Diderichsen and L. Christiansen, Cloning of a maltogenic .alpha.-amylase from Bacillus stearothermophilus, FEMS Microbiol. letters: 56: pp. 53-60 (1988) [0283] Hudson et al., Practical Immunology, Third edition (1989), Blackwell Scientific Publications, [0284] Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989 [0285] S. L. Beaucage and M. H. Caruthers, Tetrahedron Letters 22, 1981, pp. 1859-1869 [0286] Matthes et al., The EMBO J. 3, 1984, pp. 801-805. [0287] R. K. Saiki et al., Science 239, 1988, pp. 487-491, [0288] Morinaga et al., (1984, Biotechnology 2:646-639) [0289] Nelson and Long, Analytical Biochemistry 180, 1989, pp. 147-151 [0290] Hunkapiller et al., 1984, Nature 310:105-111 [0291] R. Higuchi, B. Krummel, and R. K. Saiki (1988). A general method of in vitro preparation and specific mutagenesis of DNA fragments; study of protein and DNA interactions. Nucl. Acids Res. 16:7351-7367. [0292] Dubnau et al., 1971, J. Mol. Biol. 56, pp. 209-221. [0293] Gryczan et al., 1978, J. Bacteriol. 134, pp. 318-329. [0294] S. D. Erlich, 1977, Proc. Natl. Acad. Sci. 74, pp. 1680-1682. [0295] Boel et al., 1990, Biochemistry 29, pp. 6244-6249.

Sequence CWU 1

1

581485PRTBacillus 1His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr 1 5 10 15Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ala 20 25 30Asn Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp 35 40 45Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr 50 55 60Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly65 70 75 80Thr Arg Asn Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly 85 90 95Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp 100 105 110Gly Thr Glu Ile Val Asn Ala Val Glu Val Asn Arg Ser Asn Arg Asn 115 120 125Gln Glu Thr Ser Gly Glu Tyr Ala Ile Glu Ala Trp Thr Lys Phe Asp 130 135 140Phe Pro Gly Arg Gly Asn Asn His Ser Ser Phe Lys Trp Arg Trp Tyr145 150 155 160His Phe Asp Gly Thr Asp Trp Asp Gln Ser Arg Gln Leu Gln Asn Lys 165 170 175Ile Tyr Lys Phe Arg Gly Thr Gly Lys Ala Trp Asp Trp Glu Val Asp 180 185 190Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met 195 200 205Asp His Pro Glu Val Ile His Glu Leu Arg Asn Trp Gly Val Trp Tyr 210 215 220Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His225 230 235 240Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Thr 245 250 255Thr Gly Lys Pro Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270Gly Ala Ile Glu Asn Tyr Leu Asn Lys Thr Ser Trp Asn His Ser Val 275 280 285Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly 290 295 300Gly Tyr Tyr Asp Met Arg Asn Ile Leu Asn Gly Ser Val Val Gln Lys305 310 315 320His Pro Thr His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro 325 330 335Gly Glu Ala Leu Glu Ser Phe Val Gln Gln Trp Phe Lys Pro Leu Ala 340 345 350Tyr Ala Leu Val Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr 355 360 365Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Lys Ser 370 375 380Lys Ile Asp Pro Leu Leu Gln Ala Arg Gln Thr Phe Ala Tyr Gly Thr385 390 395 400Gln His Asp Tyr Phe Asp His His Asp Ile Ile Gly Trp Thr Arg Glu 405 410 415Gly Asn Ser Ser His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp 420 425 430Gly Pro Gly Gly Asn Lys Trp Met Tyr Val Gly Lys Asn Lys Ala Gly 435 440 445Gln Val Trp Arg Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile 450 455 460Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser465 470 475 480Val Trp Val Lys Gln 4852485PRTBacillus sp. 2His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp His 1 5 10 15Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ser 20 25 30Asn Leu Arg Asn Arg Gly Ile Thr Ala Ile Trp Ile Pro Pro Ala Trp 35 40 45Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr 50 55 60Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly65 70 75 80Thr Arg Ser Gln Leu Glu Ser Ala Ile His Ala Leu Lys Asn Asn Gly 85 90 95Val Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp 100 105 110Ala Thr Glu Asn Val Leu Ala Val Glu Val Asn Pro Asn Asn Arg Asn 115 120 125Gln Glu Ile Ser Gly Asp Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp 130 135 140Phe Pro Gly Arg Gly Asn Thr Tyr Ser Asp Phe Lys Trp Arg Trp Tyr145 150 155 160His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Gln Phe Gln Asn Arg 165 170 175Ile Tyr Lys Phe Arg Gly Asp Gly Lys Ala Trp Asp Trp Glu Val Asp 180 185 190Ser Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met 195 200 205Asp His Pro Glu Val Val Asn Glu Leu Arg Arg Trp Gly Glu Trp Tyr 210 215 220Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His225 230 235 240Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Ala 245 250 255Thr Gly Lys Glu Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270Gly Ala Leu Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val 275 280 285Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly 290 295 300Gly Asn Tyr Asp Met Ala Lys Leu Leu Asn Gly Thr Val Val Gln Lys305 310 315 320His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro 325 330 335Gly Glu Ser Leu Glu Ser Phe Val Gln Glu Trp Phe Lys Pro Leu Ala 340 345 350Tyr Ala Leu Ile Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr 355 360 365Gly Asp Tyr Tyr Gly Ile Pro Thr His Ser Val Pro Ala Met Lys Ala 370 375 380Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Asn Phe Ala Tyr Gly Thr385 390 395 400Gln His Asp Tyr Phe Asp His His Asn Ile Ile Gly Trp Thr Arg Glu 405 410 415Gly Asn Thr Thr His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp 420 425 430Gly Pro Gly Gly Glu Lys Trp Met Tyr Val Gly Gln Asn Lys Ala Gly 435 440 445Gln Val Trp His Asp Ile Thr Gly Asn Lys Pro Gly Thr Val Thr Ile 450 455 460Asn Ala Asp Gly Trp Ala Asn Phe Ser Val Asn Gly Gly Ser Val Ser465 470 475 480Ile Trp Val Lys Arg 4853514PRTBacillus stearothermophilus 3Ala Ala Pro Phe Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr Leu 1 5 10 15Pro Asp Asp Gly Thr Leu Trp Thr Lys Val Ala Asn Glu Ala Asn Asn 20 25 30Leu Ser Ser Leu Gly Ile Thr Ala Leu Trp Leu Pro Pro Ala Tyr Lys 35 40 45Gly Thr Ser Arg Ser Asp Val Gly Tyr Gly Val Tyr Asp Leu Tyr Asp 50 55 60Leu Gly Glu Phe Asn Gln Lys Gly Ala Val Arg Thr Lys Tyr Gly Thr65 70 75 80Lys Ala Gln Tyr Leu Gln Ala Ile Gln Ala Ala His Ala Ala Gly Met 85 90 95Gln Val Tyr Ala Asp Val Val Phe Asp His Lys Gly Gly Ala Asp Gly 100 105 110Thr Glu Trp Val Asp Ala Val Glu Val Asn Pro Ser Asp Arg Asn Gln 115 120 125Glu Ile Ser Gly Thr Tyr Gln Ile Gln Ala Trp Thr Lys Phe Asp Phe 130 135 140Pro Gly Arg Gly Asn Thr Tyr Ser Ser Phe Lys Trp Arg Trp Tyr His145 150 155 160Phe Asp Gly Val Asp Trp Asp Glu Ser Arg Lys Leu Ser Arg Ile Tyr 165 170 175Lys Phe Arg Gly Ile Gly Lys Ala Trp Asp Trp Glu Val Asp Thr Glu 180 185 190Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Leu Asp Met Asp His 195 200 205Pro Glu Val Val Thr Glu Leu Lys Ser Trp Gly Lys Trp Tyr Val Asn 210 215 220Thr Thr Asn Ile Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys225 230 235 240Phe Ser Phe Phe Pro Asp Trp Leu Ser Asp Val Arg Ser Gln Thr Gly 245 250 255Lys Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Asp Ile Asn Lys 260 265 270Leu His Asn Tyr Ile Met Lys Thr Asn Gly Thr Met Ser Leu Phe Asp 275 280 285Ala Pro Leu His Asn Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Thr 290 295 300Phe Asp Met Arg Thr Leu Met Thr Asn Thr Leu Met Lys Asp Gln Pro305 310 315 320Thr Leu Ala Val Thr Phe Val Asp Asn His Asp Thr Glu Pro Gly Gln 325 330 335Ala Leu Gln Ser Trp Val Asp Pro Trp Phe Lys Pro Leu Ala Tyr Ala 340 345 350Phe Ile Leu Thr Arg Gln Glu Gly Tyr Pro Cys Val Phe Tyr Gly Asp 355 360 365Tyr Tyr Gly Ile Pro Gln Tyr Asn Ile Pro Ser Leu Lys Ser Lys Ile 370 375 380Asp Pro Leu Leu Ile Ala Arg Arg Asp Tyr Ala Tyr Gly Thr Gln His385 390 395 400Asp Tyr Leu Asp His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Val 405 410 415Thr Glu Lys Pro Gly Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro 420 425 430Gly Gly Ser Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val 435 440 445Phe Tyr Asp Leu Thr Gly Asn Arg Ser Asp Thr Val Thr Ile Asn Ser 450 455 460Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp465 470 475 480Val Pro Arg Lys Thr Thr Val Ser Thr Ile Ala Trp Ser Ile Thr Thr 485 490 495Arg Pro Trp Thr Asp Glu Phe Val Arg Trp Thr Glu Pro Arg Leu Val 500 505 510Ala Trp4483PRTBacillus licheniformis 4Ala Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Met Pro 1 5 10 15Asn Asp Gly Gln His Trp Arg Arg Leu Gln Asn Asp Ser Ala Tyr Leu 20 25 30Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly 35 40 45Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu 50 55 60Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys65 70 75 80Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn 85 90 95Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr 100 105 110Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val 115 120 125Ile Ser Gly Glu His Leu Ile Lys Ala Trp Thr His Phe His Phe Pro 130 135 140Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe145 150 155 160Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys 165 170 175Phe Gln Gly Lys Ala Trp Asp Trp Glu Val Ser Asn Glu Asn Gly Asn 180 185 190Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val 195 200 205Ala Ala Glu Ile Lys Arg Trp Gly Thr Trp Tyr Ala Asn Glu Leu Gln 210 215 220Leu Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe225 230 235 240Leu Arg Asp Trp Val Asn His Val Arg Glu Lys Thr Gly Lys Glu Met 245 250 255Phe Thr Val Ala Glu Tyr Trp Gln Asn Asp Leu Gly Ala Leu Glu Asn 260 265 270Tyr Leu Asn Lys Thr Asn Phe Asn His Ser Val Phe Asp Val Pro Leu 275 280 285His Tyr Gln Phe His Ala Ala Ser Thr Gln Gly Gly Gly Tyr Asp Met 290 295 300Arg Lys Leu Leu Asn Gly Thr Val Val Ser Lys His Pro Leu Lys Ser305 310 315 320Val Thr Phe Val Asp Asn His Asp Thr Gln Pro Gly Gln Ser Leu Glu 325 330 335Ser Thr Val Gln Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu 340 345 350Thr Arg Glu Ser Gly Tyr Pro Gln Val Phe Tyr Gly Asp Met Tyr Gly 355 360 365Thr Lys Gly Asp Ser Gln Arg Glu Ile Pro Ala Leu Lys His Lys Ile 370 375 380Glu Pro Ile Leu Lys Ala Arg Lys Gln Tyr Ala Tyr Gly Ala Gln His385 390 395 400Asp Tyr Phe Asp His His Asp Ile Val Gly Trp Thr Arg Glu Gly Asp 405 410 415Ser Ser Val Ala Asn Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro 420 425 430Gly Gly Ala Lys Arg Met Tyr Val Gly Arg Gln Asn Ala Gly Glu Thr 435 440 445Trp His Asp Ile Thr Gly Asn Arg Ser Glu Pro Val Val Ile Asn Ser 450 455 460Glu Gly Trp Gly Glu Phe His Val Asn Gly Gly Ser Val Ser Ile Tyr465 470 475 480Val Gln Arg5480PRTBacillus amyloliqufaciens 5Val Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Thr Pro Asn Asp 1 5 10 15Gly Gln His Trp Lys Arg Leu Gln Asn Asp Ala Glu His Leu Ser Asp 20 25 30Ile Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly Leu Ser 35 40 45Gln Ser Asp Asn Gly Tyr Gly Pro Tyr Asp Leu Tyr Asp Leu Gly Glu 50 55 60Phe Gln Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys Ser Glu65 70 75 80Leu Gln Asp Ala Ile Gly Ser Leu His Ser Arg Asn Val Gln Val Tyr 85 90 95Gly Asp Val Val Leu Asn His Lys Ala Gly Ala Asp Ala Thr Glu Asp 100 105 110Val Thr Ala Val Glu Val Asn Pro Ala Asn Arg Asn Gln Glu Thr Ser 115 120 125Glu Glu Tyr Gln Ile Lys Ala Trp Thr Asp Phe Arg Phe Pro Gly Arg 130 135 140Gly Asn Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly145 150 155 160Ala Asp Trp Asp Glu Ser Arg Lys Ile Ser Arg Ile Phe Lys Phe Arg 165 170 175Gly Glu Gly Lys Ala Trp Asp Trp Glu Val Ser Ser Glu Asn Gly Asn 180 185 190Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Tyr Asp His Pro Asp Val 195 200 205Val Ala Glu Thr Lys Lys Trp Gly Ile Trp Tyr Ala Asn Glu Leu Ser 210 215 220Leu Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Lys Phe Ser Phe225 230 235 240Leu Arg Asp Trp Val Gln Ala Val Arg Gln Ala Thr Gly Lys Glu Met 245 250 255Phe Thr Val Ala Glu Tyr Trp Gln Asn Asn Ala Gly Lys Leu Glu Asn 260 265 270Tyr Leu Asn Lys Thr Ser Phe Asn Gln Ser Val Phe Asp Val Pro Leu 275 280 285His Phe Asn Leu Gln Ala Ala Ser Ser Gln Gly Gly Gly Tyr Asp Met 290 295 300Arg Arg Leu Leu Asp Gly Thr Val Val Ser Arg His Pro Glu Lys Ala305 310 315 320Val Thr Phe Val Glu Asn His Asp Thr Gln Pro Gly Gln Ser Leu Glu 325 330 335Ser Thr Val Gln Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu 340 345 350Thr Arg Glu Ser Gly Tyr Pro Gln Val Phe Tyr Gly Asp Met Tyr Gly 355 360 365Thr Lys Gly Thr Ser Pro Lys Glu Ile Pro Ser Leu Lys Asp Asn Ile 370 375 380Glu Pro Ile Leu Lys Ala Arg Lys Glu Tyr Ala Tyr Gly Pro Gln His385 390 395 400Asp Tyr Ile Asp His Pro Asp Val Ile Gly Trp Thr Arg Glu Gly Asp 405 410 415Ser Ser Ala Ala Lys Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro 420 425 430Gly Gly Ser Lys Arg Met Tyr Ala Gly Leu Lys Asn Ala Gly Glu Thr 435 440 445Trp Tyr Asp Ile Thr Gly Asn Arg Ser Asp Thr Val Lys Ile Gly Ser 450 455 460Asp Gly Trp Gly Glu Phe His Val Asn Asp Gly Ser Val Ser Ile Tyr465 470 475 4806485PRTBacillus sp. 6His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr

Phe Glu Trp Tyr 1 5 10 15Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Asn Ser Asp Ala Ser 20 25 30Asn Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp 35 40 45Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr 50 55 60Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly65 70 75 80Thr Arg Ser Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly 85 90 95Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp 100 105 110Ala Thr Glu Met Val Arg Ala Val Glu Val Asn Pro Asn Asn Arg Asn 115 120 125Gln Glu Val Thr Gly Glu Tyr Thr Ile Glu Ala Trp Thr Arg Phe Asp 130 135 140Phe Pro Gly Arg Gly Asn Thr His Ser Ser Phe Lys Trp Arg Trp Tyr145 150 155 160His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Arg Leu Asn Asn Arg 165 170 175Ile Tyr Lys Phe Arg Gly His Gly Lys Ala Trp Asp Trp Glu Val Asp 180 185 190Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Met 195 200 205Asp His Pro Glu Val Val Asn Glu Leu Arg Asn Trp Gly Val Trp Tyr 210 215 220Thr Asn Thr Leu Gly Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His225 230 235 240Ile Lys Tyr Ser Phe Thr Arg Asp Trp Ile Asn His Val Arg Ser Ala 245 250 255Thr Gly Lys Asn Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270Gly Ala Ile Glu Asn Tyr Leu Gln Lys Thr Asn Trp Asn His Ser Val 275 280 285Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly 290 295 300Gly Asn Tyr Asp Met Arg Asn Ile Phe Asn Gly Thr Val Val Gln Arg305 310 315 320His Pro Ser His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro 325 330 335Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp Phe Lys Pro Leu Ala 340 345 350Tyr Ala Leu Thr Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr 355 360 365Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Arg Ser 370 375 380Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Lys385 390 395 400Gln Asn Asp Tyr Leu Asp His His Asn Ile Ile Gly Trp Thr Arg Glu 405 410 415Gly Asn Thr Ala His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp 420 425 430Gly Ala Gly Gly Ser Lys Trp Met Phe Val Gly Arg Asn Lys Ala Gly 435 440 445Gln Val Trp Ser Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile 450 455 460Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser465 470 475 480Ile Trp Val Asn Lys 4857485PRTBacillus sp. 7His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr 1 5 10 15Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ala 20 25 30Asn Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp 35 40 45Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr 50 55 60Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly65 70 75 80Thr Arg Asn Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly 85 90 95Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp 100 105 110Gly Thr Glu Ile Val Asn Ala Val Glu Val Asn Arg Ser Asn Arg Asn 115 120 125Gln Glu Thr Ser Gly Glu Tyr Ala Ile Glu Ala Trp Thr Lys Phe Asp 130 135 140Phe Pro Gly Arg Gly Asn Asn His Ser Ser Phe Lys Trp Arg Trp Tyr145 150 155 160His Phe Asp Gly Thr Asp Trp Asp Gln Ser Arg Gln Leu Gln Asn Lys 165 170 175Ile Tyr Lys Phe Arg Gly Thr Gly Lys Ala Trp Asp Trp Glu Val Asp 180 185 190Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met 195 200 205Asp His Pro Glu Val Ile His Glu Leu Arg Asn Trp Gly Val Trp Tyr 210 215 220Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His225 230 235 240Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Thr 245 250 255Thr Gly Lys Pro Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270Gly Ala Ile Glu Asn Tyr Leu Asn Lys Thr Ser Trp Asn His Ser Val 275 280 285Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly 290 295 300Gly Tyr Tyr Asp Met Arg Asn Ile Leu Asn Gly Ser Val Val Gln Lys305 310 315 320His Pro Thr His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro 325 330 335Gly Glu Ala Leu Glu Ser Phe Val Gln Gln Trp Phe Lys Pro Leu Ala 340 345 350Tyr Ala Leu Val Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr 355 360 365Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Lys Ser 370 375 380Lys Ile Asp Pro Leu Leu Gln Ala Arg Gln Thr Phe Ala Tyr Gly Thr385 390 395 400Gln His Asp Tyr Phe Asp His His Asp Ile Ile Gly Trp Thr Arg Glu 405 410 415Gly Asn Ser Ser His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp 420 425 430Gly Pro Gly Gly Asn Lys Trp Met Tyr Val Gly Lys Asn Lys Ala Gly 435 440 445Gln Val Trp Arg Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile 450 455 460Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser465 470 475 480Val Trp Val Lys Gln 4858485PRTBacillus sp. 8His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp His 1 5 10 15Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ser 20 25 30Asn Leu Arg Asn Arg Gly Ile Thr Ala Ile Trp Ile Pro Pro Ala Trp 35 40 45Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr 50 55 60Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly65 70 75 80Thr Arg Ser Gln Leu Glu Ser Ala Ile His Ala Leu Lys Asn Asn Gly 85 90 95Val Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp 100 105 110Ala Thr Glu Asn Val Leu Ala Val Glu Val Asn Pro Asn Asn Arg Asn 115 120 125Gln Glu Ile Ser Gly Asp Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp 130 135 140Phe Pro Gly Arg Gly Asn Thr Tyr Ser Asp Phe Lys Trp Arg Trp Tyr145 150 155 160His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Gln Phe Gln Asn Arg 165 170 175Ile Tyr Lys Phe Arg Gly Asp Gly Lys Ala Trp Asp Trp Glu Val Asp 180 185 190Ser Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met 195 200 205Asp His Pro Glu Val Val Asn Glu Leu Arg Arg Trp Gly Glu Trp Tyr 210 215 220Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His225 230 235 240Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Ala 245 250 255Thr Gly Lys Glu Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270Gly Ala Leu Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val 275 280 285Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly 290 295 300Gly Asn Tyr Asp Met Ala Lys Leu Leu Asn Gly Thr Val Val Gln Lys305 310 315 320His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro 325 330 335Gly Glu Ser Leu Glu Ser Phe Val Gln Glu Trp Phe Lys Pro Leu Ala 340 345 350Tyr Ala Leu Ile Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr 355 360 365Gly Asp Tyr Tyr Gly Ile Pro Thr His Ser Val Pro Ala Met Lys Ala 370 375 380Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Asn Phe Ala Tyr Gly Thr385 390 395 400Gln His Asp Tyr Phe Asp His His Asn Ile Ile Gly Trp Thr Arg Glu 405 410 415Gly Asn Thr Thr His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp 420 425 430Gly Pro Gly Gly Glu Lys Trp Met Tyr Val Gly Gln Asn Lys Ala Gly 435 440 445Gln Val Trp His Asp Ile Thr Gly Asn Lys Pro Gly Thr Val Thr Ile 450 455 460Asn Ala Asp Gly Trp Ala Asn Phe Ser Val Asn Gly Gly Ser Val Ser465 470 475 480Ile Trp Val Lys Arg 48591455DNABacillus 9catcataatg gaacaaatgg tactatgatg caatatttcg aatggtattt gccaaatgac 60gggaatcatt ggaacaggtt gagggatgac gcagctaact taaagagtaa agggataaca 120gctgtatgga tcccacctgc atggaagggg acttcccaga atgatgtagg ttatggagcc 180tatgatttat atgatcttgg agagtttaac cagaagggga cggttcgtac aaaatatgga 240acacgcaacc agctacaggc tgcggtgacc tctttaaaaa ataacggcat tcaggtatat 300ggtgatgtcg tcatgaatca taaaggtgga gcagatggta cggaaattgt aaatgcggta 360gaagtgaatc ggagcaaccg aaaccaggaa acctcaggag agtatgcaat agaagcgtgg 420acaaagtttg attttcctgg aagaggaaat aaccattcca gctttaagtg gcgctggtat 480cattttgatg ggacagattg ggatcagtca cgccagcttc aaaacaaaat atataaattc 540aggggaacag gcaaggcctg ggactgggaa gtcgatacag agaatggcaa ctatgactat 600cttatgtatg cagacgtgga tatggatcac ccagaagtaa tacatgaact tagaaactgg 660ggagtgtggt atacgaatac actgaacctt gatggattta gaatagatgc agtgaaacat 720ataaaatata gctttacgag agattggctt acacatgtgc gtaacaccac aggtaaacca 780atgtttgcag tggctgagtt ttggaaaaat gaccttggtg caattgaaaa ctatttgaat 840aaaacaagtt ggaatcactc ggtgtttgat gttcctctcc actataattt gtacaatgca 900tctaatagcg gtggttatta tgatatgaga aatattttaa atggttctgt ggtgcaaaaa 960catccaacac atgccgttac ttttgttgat aaccatgatt ctcagcccgg ggaagcattg 1020gaatcctttg ttcaacaatg gtttaaacca cttgcatatg cattggttct gacaagggaa 1080caaggttatc cttccgtatt ttatggggat tactacggta tcccaaccca tggtgttccg 1140gctatgaaat ctaaaataga ccctcttctg caggcacgtc aaacttttgc ctatggtacg 1200cagcatgatt actttgatca tcatgatatt atcggttgga caagagaggg aaatagctcc 1260catccaaatt caggccttgc caccattatg tcagatggtc caggtggtaa caaatggatg 1320tatgtgggga aaaataaagc gggacaagtt tggagagata ttaccggaaa taggacaggc 1380accgtcacaa ttaatgcaga cggatggggt aatttctctg ttaatggagg gtccgtttcg 1440gtttgggtga agcaa 1455101455DNABacillus sp. 10catcataatg ggacaaatgg gacgatgatg caatactttg aatggcactt gcctaatgat 60gggaatcact ggaatagatt aagagatgat gctagtaatc taagaaatag aggtataacc 120gctatttgga ttccgcctgc ctggaaaggg acttcgcaaa atgatgtggg gtatggagcc 180tatgatcttt atgatttagg ggaatttaat caaaagggga cggttcgtac taagtatggg 240acacgtagtc aattggagtc tgccatccat gctttaaaga ataatggcgt tcaagtttat 300ggggatgtag tgatgaacca taaaggagga gctgatgcta cagaaaacgt tcttgctgtc 360gaggtgaatc caaataaccg gaatcaagaa atatctgggg actacacaat tgaggcttgg 420actaagtttg attttccagg gaggggtaat acatactcag actttaaatg gcgttggtat 480catttcgatg gtgtagattg ggatcaatca cgacaattcc aaaatcgtat ctacaaattc 540cgaggtgatg gtaaggcatg ggattgggaa gtagattcgg aaaatggaaa ttatgattat 600ttaatgtatg cagatgtaga tatggatcat ccggaggtag taaatgagct tagaagatgg 660ggagaatggt atacaaatac attaaatctt gatggattta ggatcgatgc ggtgaagcat 720attaaatata gctttacacg tgattggttg acccatgtaa gaaacgcaac gggaaaagaa 780atgtttgctg ttgctgaatt ttggaaaaat gatttaggtg ccttggagaa ctatttaaat 840aaaacaaact ggaatcattc tgtctttgat gtcccccttc attataatct ttataacgcg 900tcaaatagtg gaggcaacta tgacatggca aaacttctta atggaacggt tgttcaaaag 960catccaatgc atgccgtaac ttttgtggat aatcacgatt ctcaacctgg ggaatcatta 1020gaatcatttg tacaagaatg gtttaagcca cttgcttatg cgcttatttt aacaagagaa 1080caaggctatc cctctgtctt ctatggtgac tactatggaa ttccaacaca tagtgtccca 1140gcaatgaaag ccaagattga tccaatctta gaggcgcgtc aaaattttgc atatggaaca 1200caacatgatt attttgacca tcataatata atcggatgga cacgtgaagg aaataccacg 1260catcccaatt caggacttgc gactatcatg tcggatgggc cagggggaga gaaatggatg 1320tacgtagggc aaaataaagc aggtcaagtt tggcatgaca taactggaaa taaaccagga 1380acagttacga tcaatgcaga tggatgggct aatttttcag taaatggagg atctgtttcc 1440atttgggtga aacga 1455111548DNABacillus stearothermophilus 11gccgcaccgt ttaacggcac catgatgcag tattttgaat ggtacttgcc ggatgatggc 60acgttatgga ccaaagtggc caatgaagcc aacaacttat ccagccttgg catcaccgct 120ctttggctgc cgcccgctta caaaggaaca agccgcagcg acgtagggta cggagtatac 180gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atacggaaca 240aaagctcaat atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtacgcc 300gatgtcgtgt tcgaccataa aggcggcgct gacggcacgg aatgggtgga cgccgtcgaa 360gtcaatccgt ccgaccgcaa ccaagaaatc tcgggcacct atcaaatcca agcatggacg 420aaatttgatt ttcccgggcg gggcaacacc tactccagct ttaagtggcg ctggtaccat 480tttgacggcg ttgattggga cgaaagccga aaattgagcc gcatttacaa attccgcggc 540atcggcaaag cgtgggattg ggaagtagac acggaaaacg gaaactatga ctacttaatg 600tatgccgacc ttgatatgga tcatcccgaa gtcgtgaccg agctgaaaaa ctgggggaaa 660tggtatgtca acacaacgaa cattgatggg ttccggcttg atgccgtcaa gcatattaag 720ttcagttttt ttcctgattg gttgtcgtat gtgcgttctc agactggcaa gccgctattt 780accgtcgggg aatattggag ctatgacatc aacaagttgc acaattacat tacgaaaaca 840gacggaacga tgtctttgtt tgatgccccg ttacacaaca aattttatac cgcttccaaa 900tcagggggcg catttgatat gcgcacgtta atgaccaata ctctcatgaa agatcaaccg 960acattggccg tcaccttcgt tgataatcat gacaccgaac ccggccaagc gctgcagtca 1020tgggtcgacc catggttcaa accgttggct tacgccttta ttctaactcg gcaggaagga 1080tacccgtgcg tcttttatgg tgactattat ggcattccac aatataacat tccttcgctg 1140aaaagcaaaa tcgatccgct cctcatcgcg cgcagggatt atgcttacgg aacgcaacat 1200gattatcttg atcactccga catcatcggg tggacaaggg aagggggcac tgaaaaacca 1260ggatccggac tggccgcact gatcaccgat gggccgggag gaagcaaatg gatgtacgtt 1320ggcaaacaac acgctggaaa agtgttctat gaccttaccg gcaaccggag tgacaccgtc 1380accatcaaca gtgatggatg gggggaattc aaagtcaatg gcggttcggt ttcggtttgg 1440gttcctagaa aaacgaccgt ttctaccatc gctcggccga tcacaacccg accgtggact 1500ggtgaattcg tccgttggac cgaaccacgg ttggtggcat ggccttga 1548121920DNABacillus licheniformisCDS(421)...(1872) 12cggaagattg gaagtacaaa aataagcaaa agattgtcaa tcatgtcatg agccatgcgg 60gagacggaaa aatcgtctta atgcacgata tttatgcaac gttcgcagat gctgctgaag 120agattattaa aaagctgaaa gcaaaaggct atcaattggt aactgtatct cagcttgaag 180aagtgaagaa gcagagaggc tattgaataa atgagtagaa gcgccatatc ggcgcttttc 240ttttggaaga aaatataggg aaaatggtac ttgttaaaaa ttcggaatat ttatacaaca 300tcatatgttt cacattgaaa ggggaggaga atcatgaaac aacaaaaacg gctttacgcc 360cgattgctga cgctgttatt tgcgctcatc ttcttgctgc ctcattctgc agcagcggcg 420gca aat ctt aat ggg acg ctg atg cag tat ttt gaa tgg tac atg ccc 468Ala Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Met Pro 1 5 10 15aat gac ggc caa cat tgg agg cgt ttg caa aac gac tcg gca tat ttg 516Asn Asp Gly Gln His Trp Arg Arg Leu Gln Asn Asp Ser Ala Tyr Leu 20 25 30gct gaa cac ggt att act gcc gtc tgg att ccc ccg gca tat aag gga 564Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly 35 40 45acg agc caa gcg gat gtg ggc tac ggt gct tac gac ctt tat gat tta 612Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu 50 55 60ggg gag ttt cat caa aaa ggg acg gtt cgg aca aag tac ggc aca aaa 660Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys 65 70 75 80gga gag ctg caa tct gcg atc aaa agt ctt cat tcc cgc gac att aac 708Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn 85 90 95gtt tac ggg gat gtg gtc atc aac cac aaa ggc ggc gct gat gcg acc 756Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr 100 105

110gaa gat gta acc gcg gtt gaa gtc gat ccc gct gac cgc aac cgc gta 804Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val 115 120 125att tca gga gaa cac cta att aaa gcc tgg aca cat ttt cat ttt ccg 852Ile Ser Gly Glu His Leu Ile Lys Ala Trp Thr His Phe His Phe Pro 130 135 140ggg cgc ggc agc aca tac agc gat ttt aaa tgg cat tgg tac cat ttt 900Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe145 150 155 160gac gga acc gat tgg gac gag tcc cga aag ctg aac cgc atc tat aag 948Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys 165 170 175ttt caa gga aag gct tgg gat tgg gaa gtt tcc aat gaa aac ggc aac 996Phe Gln Gly Lys Ala Trp Asp Trp Glu Val Ser Asn Glu Asn Gly Asn 180 185 190tat gat tat ttg atg tat gcc gac atc gat tat gac cat cct gat gtc 1044Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val 195 200 205gca gca gaa att aag aga tgg ggc act tgg tat gcc aat gaa ctg caa 1092Ala Ala Glu Ile Lys Arg Trp Gly Thr Trp Tyr Ala Asn Glu Leu Gln 210 215 220ttg gac ggt ttc cgt ctt gat gct gtc aaa cac att aaa ttt tct ttt 1140Leu Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe225 230 235 240ttg cgg gat tgg gtt aat cat gtc agg gaa aaa acg ggg aag gaa atg 1188Leu Arg Asp Trp Val Asn His Val Arg Glu Lys Thr Gly Lys Glu Met 245 250 255ttt acg gta gct gaa tat tgg cag aat gac ttg ggc gcg ctg gaa aac 1236Phe Thr Val Ala Glu Tyr Trp Gln Asn Asp Leu Gly Ala Leu Glu Asn 260 265 270tat ttg aac aaa aca aat ttt aat cat tca gtg ttt gac gtg ccg ctt 1284Tyr Leu Asn Lys Thr Asn Phe Asn His Ser Val Phe Asp Val Pro Leu 275 280 285cat tat cag ttc cat gct gca tcg aca cag gga ggc ggc tat gat atg 1332His Tyr Gln Phe His Ala Ala Ser Thr Gln Gly Gly Gly Tyr Asp Met 290 295 300agg aaa ttg ctg aac ggt acg gtc gtt tcc aag cat ccg ttg aaa tcg 1380Arg Lys Leu Leu Asn Gly Thr Val Val Ser Lys His Pro Leu Lys Ser305 310 315 320gtt aca ttt gtc gat aac cat gat aca cag ccg ggg caa tcg ctt gag 1428Val Thr Phe Val Asp Asn His Asp Thr Gln Pro Gly Gln Ser Leu Glu 325 330 335tcg act gtc caa aca tgg ttt aag ccg ctt gct tac gct ttt att ctc 1476Ser Thr Val Gln Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu 340 345 350aca agg gaa tct gga tac cct cag gtt ttc tac ggg gat atg tac ggg 1524Thr Arg Glu Ser Gly Tyr Pro Gln Val Phe Tyr Gly Asp Met Tyr Gly 355 360 365acg aaa gga gac tcc cag cgc gaa att cct gcc ttg aaa cac aaa att 1572Thr Lys Gly Asp Ser Gln Arg Glu Ile Pro Ala Leu Lys His Lys Ile 370 375 380gaa ccg atc tta aaa gcg aga aaa cag tat gcg tac gga gca cag cat 1620Glu Pro Ile Leu Lys Ala Arg Lys Gln Tyr Ala Tyr Gly Ala Gln His385 390 395 400gat tat ttc gac cac cat gac att gtc ggc tgg aca agg gaa ggc gac 1668Asp Tyr Phe Asp His His Asp Ile Val Gly Trp Thr Arg Glu Gly Asp 405 410 415agc tcg gtt gca aat tca ggt ttg gcg gca tta ata aca gac gga ccc 1716Ser Ser Val Ala Asn Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro 420 425 430ggt ggg gca aag cga atg tat gtc ggc cgg caa aac gcc ggt gag aca 1764Gly Gly Ala Lys Arg Met Tyr Val Gly Arg Gln Asn Ala Gly Glu Thr 435 440 445tgg cat gac att acc gga aac cgt tcg gag ccg gtt gtc atc aat tcg 1812Trp His Asp Ile Thr Gly Asn Arg Ser Glu Pro Val Val Ile Asn Ser 450 455 460gaa ggc tgg gga gag ttt cac gta aac ggc ggg tcg gtt tca att tat 1860Glu Gly Trp Gly Glu Phe His Val Asn Gly Gly Ser Val Ser Ile Tyr465 470 475 480gtt caa aga tag aagagcagag aggacggatt tcctgaagga aatccgtttt 1912Val Gln Arg *tttatttt 1920131455DNABacillus sp. 13catcataatg gaacaaatgg tactatgatg caatatttcg aatggtattt gccaaatgac 60gggaatcatt ggaacaggtt gagggatgac gcagctaact taaagagtaa agggataaca 120gctgtatgga tcccacctgc atggaagggg acttcccaga atgatgtagg ttatggagcc 180tatgatttat atgatcttgg agagtttaac cagaagggga cggttcgtac aaaatatgga 240acacgcaacc agctacaggc tgcggtgacc tctttaaaaa ataacggcat tcaggtatat 300ggtgatgtcg tcatgaatca taaaggtgga gcagatggta cggaaattgt aaatgcggta 360gaagtgaatc ggagcaaccg aaaccaggaa acctcaggag agtatgcaat agaagcgtgg 420acaaagtttg attttcctgg aagaggaaat aaccattcca gctttaagtg gcgctggtat 480cattttgatg ggacagattg ggatcagtca cgccagcttc aaaacaaaat atataaattc 540aggggaacag gcaaggcctg ggactgggaa gtcgatacag agaatggcaa ctatgactat 600cttatgtatg cagacgtgga tatggatcac ccagaagtaa tacatgaact tagaaactgg 660ggagtgtggt atacgaatac actgaacctt gatggattta gaatagatgc agtgaaacat 720ataaaatata gctttacgag agattggctt acacatgtgc gtaacaccac aggtaaacca 780atgtttgcag tggctgagtt ttggaaaaat gaccttggtg caattgaaaa ctatttgaat 840aaaacaagtt ggaatcactc ggtgtttgat gttcctctcc actataattt gtacaatgca 900tctaatagcg gtggttatta tgatatgaga aatattttaa atggttctgt ggtgcaaaaa 960catccaacac atgccgttac ttttgttgat aaccatgatt ctcagcccgg ggaagcattg 1020gaatcctttg ttcaacaatg gtttaaacca cttgcatatg cattggttct gacaagggaa 1080caaggttatc cttccgtatt ttatggggat tactacggta tcccaaccca tggtgttccg 1140gctatgaaat ctaaaataga ccctcttctg caggcacgtc aaacttttgc ctatggtacg 1200cagcatgatt actttgatca tcatgatatt atcggttgga caagagaggg aaatagctcc 1260catccaaatt caggccttgc caccattatg tcagatggtc caggtggtaa caaatggatg 1320tatgtgggga aaaataaagc gggacaagtt tggagagata ttaccggaaa taggacaggc 1380accgtcacaa ttaatgcaga cggatggggt aatttctctg ttaatggagg gtccgtttcg 1440gtttgggtga agcaa 1455141455DNABacillus sp. 14catcataatg ggacaaatgg gacgatgatg caatactttg aatggcactt gcctaatgat 60gggaatcact ggaatagatt aagagatgat gctagtaatc taagaaatag aggtataacc 120gctatttgga ttccgcctgc ctggaaaggg acttcgcaaa atgatgtggg gtatggagcc 180tatgatcttt atgatttagg ggaatttaat caaaagggga cggttcgtac taagtatggg 240acacgtagtc aattggagtc tgccatccat gctttaaaga ataatggcgt tcaagtttat 300ggggatgtag tgatgaacca taaaggagga gctgatgcta cagaaaacgt tcttgctgtc 360gaggtgaatc caaataaccg gaatcaagaa atatctgggg actacacaat tgaggcttgg 420actaagtttg attttccagg gaggggtaat acatactcag actttaaatg gcgttggtat 480catttcgatg gtgtagattg ggatcaatca cgacaattcc aaaatcgtat ctacaaattc 540cgaggtgatg gtaaggcatg ggattgggaa gtagattcgg aaaatggaaa ttatgattat 600ttaatgtatg cagatgtaga tatggatcat ccggaggtag taaatgagct tagaagatgg 660ggagaatggt atacaaatac attaaatctt gatggattta ggatcgatgc ggtgaagcat 720attaaatata gctttacacg tgattggttg acccatgtaa gaaacgcaac gggaaaagaa 780atgtttgctg ttgctgaatt ttggaaaaat gatttaggtg ccttggagaa ctatttaaat 840aaaacaaact ggaatcattc tgtctttgat gtcccccttc attataatct ttataacgcg 900tcaaatagtg gaggcaacta tgacatggca aaacttctta atggaacggt tgttcaaaag 960catccaatgc atgccgtaac ttttgtggat aatcacgatt ctcaacctgg ggaatcatta 1020gaatcatttg tacaagaatg gtttaagcca cttgcttatg cgcttatttt aacaagagaa 1080caaggctatc cctctgtctt ctatggtgac tactatggaa ttccaacaca tagtgtccca 1140gcaatgaaag ccaagattga tccaatctta gaggcgcgtc aaaattttgc atatggaaca 1200caacatgatt attttgacca tcataatata atcggatgga cacgtgaagg aaataccacg 1260catcccaatt caggacttgc gactatcatg tcggatgggc cagggggaga gaaatggatg 1320tacgtagggc aaaataaagc aggtcaagtt tggcatgaca taactggaaa taaaccagga 1380acagttacga tcaatgcaga tggatgggct aatttttcag taaatggagg atctgtttcc 1440atttgggtga aacga 14551560DNAArtifiicial sequenceprimer 15caaaatcgta tctacaaatt cmrkrsyarg dvktgggatt sggaagtaga ttcggaaaat 601621DNAArtificial SequencePrimer 16gaatttgtag atacgatttt g 211724DNAArtificial SequencePrimer 17cgattgctga cgctgttatt tgcg 241824DNAArtificial SequencePrimer 18cttgttccct tgtcagaacc aatg 241930DNAArtificial SequencePrimer 19gtcatagttg ccgaaatctg tatcgacttc 302038DNAArtificial SequencePrimer 20cccagtccca cgtacgtccc ctgaatttat atattttg 382138DNAArtificial Sequencemisc_feature(0)...(0)n on position 12 is 25% A, 25% C, 25% G, 25% T Primer 21cccagtccca gntctttccc ctgaatttat atattttg 382225DNAArtificial SequencePrimer 22gcgtggacaa agtttgattt tcctg 252321DNAArtificial SequencePrimer 23cctaatgatg ggaatcactg g 212424DNAArtificial SequencePrimer 24gcattggatg cttttgaaca accg 242526DNAArtificial SequencePrimer 25cgcaaaatga tatcgggtat ggagcc 262629DNAArtificial SequencePrimer 26gtgatgaacc acswaggtgg agctgatgc 292730DNAArtificial SequencePrimer 27gatggtgtat ggrycaatca cgacaattcc 302828DNAArtificial SequencePrimer 28ggtgtatggg ataactcacg acaattcc 282928DNAArtificial SequencePrimer 29ggtgtatggg atctctcacg acaattcc 283032DNAArtificial SequencePrimer 30gggatcaatc acgaaatttc caaaatcgta tc 323132DNAArtificial SequencePrimer 31gggatcaatc acgactcttc caaaatcgta tc 323234DNAArtificial SequencePrimer 32ggaaattatg attatatcat gtatgcagat gtag 343330DNAArtificial SequencePrimer 33gctgaatttt ggtcgaatga tttaggtgcc 303430DNAArtificial SequencePrimer 34gctgaatttt ggtcgaatga tttaggtgcc 303527DNAArtificial SequencePrimer 35gaattttgga agtacgattt aggtcgg 273629DNAArtificial SequencePrimer 36ggaaaaacga trycggtgcc ttggagaac 293727DNAArtificial SequencePrimer 37gatttaggtg cctrycagaa ctattta 273826DNAArtificial SequencePrimer 38cccccttcat gagaatcttt ataacg 263925DNAArtificial SequencePrimer 39gaatccgaac ctcattacac attcg 254028DNAArtificial SequencePrimer 40cggatggact cgagaaggaa ataccacg 284131DNAArtificial SequencePrimer 41cgtagggcaa aatcaggccg gtcaagtttg g 314231DNAArtificial SequencePrimer 42cataactgga aatcgcccgg gaacagttac g 314326DNAArtificial SequencePrimer 43ctggaaataa awccggaaca gttacg 264432DNAArtificial SequencePrimer 44ggaaataaac caggacccgt tacgatcaat gc 324528DNAArtificial SequencePrimer 45gaggcttgga ctaggtttga ttttccag 284630DNAArtificial SequencePrimer 46gctgaatttt ggcgcaatga tttaggtgcc 304734DNAArtificial SequencePrimer 47gtgtttgacg tcccgcttca tgagaattta cagg 344834DNAArtificial SequencePrimer 48gtgtttgacg tcccgcttca taagaattta cagg 344934DNAArtificial SequencePrimer 49gtgtttgacg tcccgcttca tgccaattta cagg 345032DNAArtificial SequencePrimer 50agggaatccg gataccctga ggttttctac gg 325134DNAArtificial SequencePrimer 51gatgtggttt tggatcataa ggccggcgct gatg 345222DNAArtificial SequencePrimer 52ctgttattaa tgccgccaaa cc 225324DNAArtificial SequencePrimer 53ggaaaagaaa tgtttacggt tgcg 245425DNAArtificial SequencePrimer 54gaaatgaagc ggaacatcaa acacg 255520DNAArtificial SequencePrimer 55gtatgattta ggagaattcc 205633DNAArtificial SequencePrimer 56ccagcgcgcc taggtcacgc tgccaatatt cag 335733DNAArtificial SequencePrimer 57ccagcgcgcc taggtcatcc tgccaatatt cag 33582084DNABacillus amyloliquefaciensCDS(343)...(1794) 58gccccgcaca tacgaaaaga ctggctgaaa acattgagcc tttgatgact gatgatttgg 60ctgaagaagt ggatcgattg tttgagaaaa gaagaagacc ataaaaatac cttgtctgtc 120atcagacagg gtatttttta tgctgtccag actgtccgct gtgtaaaaat aaggaataaa 180ggggggttgt tattatttta ctgatatgta aaatataatt tgtataagaa aatgagaggg 240agaggaaaca tgattcaaaa acgaaagcgg acagtttcgt tcagacttgt gcttatgtgc 300acgctgttat ttgtcagttt gccgattaca aaaacatcag cc gta aat ggc acg 354Val Asn Gly Thr 1ctg atg cag tat ttt gaa tgg tat acg ccg aac gac ggc cag cat tgg 402Leu Met Gln Tyr Phe Glu Trp Tyr Thr Pro Asn Asp Gly Gln His Trp 5 10 15 20aaa cga ttg cag aat gat gcg gaa cat tta tcg gat atc gga atc act 450Lys Arg Leu Gln Asn Asp Ala Glu His Leu Ser Asp Ile Gly Ile Thr 25 30 35gcc gtc tgg att cct ccc gca tac aaa gga ttg agc caa tcc gat aac 498Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly Leu Ser Gln Ser Asp Asn 40 45 50gga tac gga cct tat gat ttg tat gat tta gga gaa ttc cag caa aaa 546Gly Tyr Gly Pro Tyr Asp Leu Tyr Asp Leu Gly Glu Phe Gln Gln Lys 55 60 65ggg acg gtc aga acg aaa tac ggc aca aaa tca gag ctt caa gat gcg 594Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys Ser Glu Leu Gln Asp Ala 70 75 80atc ggc tca ctg cat tcc cgg aac gtc caa gta tac gga gat gtg gtt 642Ile Gly Ser Leu His Ser Arg Asn Val Gln Val Tyr Gly Asp Val Val 85 90 95 100ttg aat cat aag gct ggt gct gat gca aca gaa gat gta act gcc gtc 690Leu Asn His Lys Ala Gly Ala Asp Ala Thr Glu Asp Val Thr Ala Val 105 110 115gaa gtc aat ccg gcc aat aga aat cag gaa act tcg gag gaa tat caa 738Glu Val Asn Pro Ala Asn Arg Asn Gln Glu Thr Ser Glu Glu Tyr Gln 120 125 130atc aaa gcg tgg acg gat ttt cgt ttt ccg ggc cgt gga aac acg tac 786Ile Lys Ala Trp Thr Asp Phe Arg Phe Pro Gly Arg Gly Asn Thr Tyr 135 140 145agt gat ttt aaa tgg cat tgg tat cat ttc gac gga gcg gac tgg gat 834Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly Ala Asp Trp Asp 150 155 160gaa tcc cgg aag atc agc cgc atc ttt aag ttt cgt ggg gaa gga aaa 882Glu Ser Arg Lys Ile Ser Arg Ile Phe Lys Phe Arg Gly Glu Gly Lys165 170 175 180gcg tgg gat tgg gaa gta tca agt gaa aac ggc aac tat gac tat tta 930Ala Trp Asp Trp Glu Val Ser Ser Glu Asn Gly Asn Tyr Asp Tyr Leu 185 190 195atg tat gct gat gtt gac tac gac cac cct gat gtc gtg gca gag aca 978Met Tyr Ala Asp Val Asp Tyr Asp His Pro Asp Val Val Ala Glu Thr 200 205 210aaa aaa tgg ggt atc tgg tat gcg aat gaa ctg tca tta gac ggc ttc 1026Lys Lys Trp Gly Ile Trp Tyr Ala Asn Glu Leu Ser Leu Asp Gly Phe 215 220 225cgt att gat gcc gcc aaa cat att aaa ttt tca ttt ctg cgt gat tgg 1074Arg Ile Asp Ala Ala Lys His Ile Lys Phe Ser Phe Leu Arg Asp Trp 230 235 240gtt cag gcg gtc aga cag gcg acg gga aaa gaa atg ttt acg gtt gcg 1122Val Gln Ala Val Arg Gln Ala Thr Gly Lys Glu Met Phe Thr Val Ala245 250 255 260gag tat tgg cag aat aat gcc ggg aaa ctc gaa aac tac ttg aat aaa 1170Glu Tyr Trp Gln Asn Asn Ala Gly Lys Leu Glu Asn Tyr Leu Asn Lys 265 270 275aca agc ttt aat caa tcc gtg ttt gat gtt ccg ctt cat ttc aat tta 1218Thr Ser Phe Asn Gln Ser Val Phe Asp Val Pro Leu His Phe Asn Leu 280 285 290cag gcg gct tcc tca caa gga ggc gga tat gat atg agg cgt ttg ctg 1266Gln Ala Ala Ser Ser Gln Gly Gly Gly Tyr Asp Met Arg Arg Leu Leu 295 300 305gac ggt acc gtt gtg tcc agg cat ccg gaa aag gcg gtt aca ttt gtt 1314Asp Gly Thr Val Val Ser Arg His Pro Glu Lys Ala Val Thr Phe Val 310 315 320gaa aat cat gac aca cag ccg gga cag tca ttg gaa tcg aca gtc caa 1362Glu Asn His Asp Thr Gln Pro Gly Gln Ser Leu Glu Ser Thr Val Gln325 330 335 340act tgg ttt aaa ccg ctt gca tac gcc ttt att ttg aca aga gaa tcc 1410Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu Thr Arg Glu Ser 345 350 355ggt tat cct cag gtg ttc tat ggg gat atg tac ggg aca aaa ggg aca 1458Gly Tyr Pro Gln Val Phe Tyr Gly Asp Met Tyr Gly Thr Lys Gly Thr 360 365 370tcg cca aag gaa att ccc tca ctg aaa gat aat ata gag ccg att tta 1506Ser Pro Lys Glu Ile Pro Ser Leu Lys Asp Asn Ile Glu Pro Ile Leu 375 380 385aaa gcg cgt aag gag tac gca tac ggg ccc cag cac gat tat att gac 1554Lys Ala Arg Lys Glu Tyr Ala Tyr Gly Pro Gln His Asp Tyr Ile Asp 390 395 400cac ccg gat gtg atc gga tgg acg agg gaa ggt

gac agc tcc gcc gcc 1602His Pro Asp Val Ile Gly Trp Thr Arg Glu Gly Asp Ser Ser Ala Ala405 410 415 420aaa tca ggt ttg gcc gct tta atc acg gac gga ccc ggc gga tca aag 1650Lys Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro Gly Gly Ser Lys 425 430 435cgg atg tat gcc ggc ctg aaa aat gcc ggc gag aca tgg tat gac ata 1698Arg Met Tyr Ala Gly Leu Lys Asn Ala Gly Glu Thr Trp Tyr Asp Ile 440 445 450acg ggc aac cgt tca gat act gta aaa atc gga tct gac ggc tgg gga 1746Thr Gly Asn Arg Ser Asp Thr Val Lys Ile Gly Ser Asp Gly Trp Gly 455 460 465gag ttt cat gta aac gat ggg tcc gtc tcc att tat gtt cag aaa taa 1794Glu Phe His Val Asn Asp Gly Ser Val Ser Ile Tyr Val Gln Lys 470 475 480ggtaataaaa aaacacctcc aagctgagtg cgggtatcag cttggaggtg cgtttatttt 1854ttcagccgta tgacaaggtc ggcatcaggt gtgacaaata cggtatgctg gctgtcatag 1914gtgacaaatc cgggttttgc gccgtttggc tttttcacat gtctgatttt tgtataatca 1974acaggcacgg agccggaatc tttcgccttg gaaaaataag cggcgatcgt agctgcttcc 2034aatatggatt gttcatcggg atcgctgctt ttaatcacaa cgtgggatcc 2084

Claims

1-39. (canceled)

40. A variant alpha-amylase, which variant has alpha-amylase activity, has at least 90% homology with the amino acid sequence shown in SEQ ID. NO. 3, and which comprises one or more of the following substitutions (using SEQ SD NO:3 for numbering): TABLE-US-00047 (a) R179A, D, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V; (b) G180A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, or V; (c) I181A, R, N, C, E, Q, G, H, L, K, M, F, P, S, T, W, Y, or V; (d) G182A, R, D, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, or V.

41. A variant alpha-amylase, which variant has alpha-amylase activity, has at least 95% homology with the amino acid sequence shown in SEQ ID. NO. 3, and which comprises one or more of the following substitutions (using SEQ ID NO:3 for numbering): TABLE-US-00048 (a) R179A, D, N, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or v; (b) G180A, D, R, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, or V; (c) I181A, R, N, C, E, Q, G, H, L, K, M, F, P, S, T, W, Y, or V; (d) G182A, R, D, N, C, E, Q, H, I, L, K, M, F, P, S, T, W, Y, or V.

42. The variant of claim 40, wherein the variant comprises a substitution of R179A,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y, or V.

43. The variant of claim 40, wherein the variant comprises a substitution of G180A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y, or V.

44. The variant of claim 40, wherein the variant comprises a substitution of I181A,R,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y, or V.

45. The variant of claim 40, wherein the variant comprises a substitution of G182A,R,D,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y, or V.

46. The variant of claim 41, wherein the variant comprises a substitution of R179A,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,TlW,Y, or V.

47. The variant of claim 41, wherein the variant comprises a substitution of G180A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y, or V.

48. The variant of claim 41, wherein the variant comprises a substitution of I181A,R,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,or V.

49. The variant of claim 41, wherein the variant comprises a substitution of G182A,R,D,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y, or V.